

Distinct functional roles for the M4 α-helix from each homologous subunit in the heteropentameric ligand-gated ion channel nAChR

Received for publication, November 4, 2021, and in revised form, May 30, 2022 Published, Papers in Press, June 7, 2022, https://doi.org/10.1016/j.jbc.2022.102104

Mackenzie J. Thompson, Jaimee A. Domville, Claire H. Edrington, Angelica Venes, Patrick M. Giguère, and John E. Baenziger*

From the Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, Ontario, Canada

Edited by Mike Shipston

The outermost lipid-exposed α -helix (M4) in each of the homologous α , β , δ , and γ/ϵ subunits of the muscle nicotinic acetylcholine receptor (nAChR) has previously been proposed to act as a lipid sensor. However, the mechanism by which this sensor would function is not clear. To explore how the M4 αhelix from each subunit in human adult muscle nAChR influences function, and thus explore its putative role in lipid sensing, we functionally characterized alanine mutations at every residue in $\alpha M4$, $\beta M4$, $\delta M4$, and $\epsilon M4$, along with both alanine and deletion mutations in the post-M4 region of each subunit. Although no critical interactions involving residues on M4 or in post-M4 were identified, we found that numerous mutations at the M4-M1/M3 interface altered the agonistinduced response. In addition, homologous mutations in M4 in different subunits were found to have different effects on channel function. The functional effects of multiple mutations either along M4 in one subunit or at homologous positions of M4 in different subunits were also found to be additive. Finally, when characterized in both Xenopus oocytes and human embryonic kidney 293T cells, select aM4 mutations displayed cell-specific phenotypes, possibly because of the different membrane lipid environments. Collectively, our data suggest different functional roles for the M4 a-helix in each heteromeric nAChR subunit and predict that lipid sensing involving M4 occurs primarily through the cumulative interactions at the M4–M1/M3 interface, as opposed to the alteration of specific interactions that are critical to channel function.

Although the functional sensitivity of the muscle-type $(\alpha_2\beta\gamma\delta)$ nicotinic acetylcholine receptor (nAChR) from *Torpedo* to lipids has been extensively characterized (1–3), the mechanisms by which lipids influence function remain poorly understood. It is known that lipids alter function predominantly *via* a conformational selection mechanism whereby some membranes preferentially stabilize the activatable resting state, whereas others preferentially stabilize nonactivatable desensitized or uncoupled states (4–7). Several observations also suggest that the M4 α -helix from each of the five subunits plays a central role in lipid sensing (8). M4 is located at the

periphery of the transmembrane domain (TMD) of each subunit, where it forms extensive contacts with the lipid bilayer (Fig. 1). Numerous mutations in M4 influence channel function, including an α C418W potentiating mutation that leads to a congenital myasthenic syndrome (CMS) (9–13). Lipids are also observed bound to the interfaces between M4 and the adjacent M1 and M3 α -helices in the *Torpedo* nAChR and in other pentameric ligand-gated ion channels (pLGICs), although the functional roles of these bound lipids remain to be defined (3, 14–17).

One plausible mechanism by which lipids influence nAChR function is by modulating interactions between M4 and the remainder of the TMD. More specifically, lipid-induced changes in the position of M4 relative to M1 and M3 could alter interhelical packing of the entire TMD in a manner that directly influences channel gating or desensitization, as was recently suggested for lipid binding to the M4-M1 interface of the prokaryotic pLGIC, Erwinia ligand-gated ion channel (ELIC) (18). Altered M4-M1/M3 interactions could also reposition the M4 C terminus (post-M4) to interact with structures in the extracellular domain (ECD) to alter the physical coupling between the agonist-binding ECD and channel-gating TMD (Fig. 1B). The latter hypothesis is supported by the observation that post-M4 is critical to folding and function in some pLGICs (19-24), albeit not in others (25, 26).

As a first step toward understanding the mechanisms by which the nAChR senses its lipid environment, we set out to characterize the functional role of the M4 α-helix from each subunit in a heteropentameric muscle-type nAChR. In a previous publication, we probed the functional role of M4 from the α subunit (α M4) of the human adult muscle nAChR (26). Here, we extend this study to include M4 from each of the remaining β (β M4), δ (δ M4), and ϵ (ϵ M4) subunits. Through mutagenesis and electrophysiological recordings, we identify interactions between M4 and M1/M3 in each subunit that influence channel function and that could thus participate in lipid sensing, although no critical functional interactions were identified. In addition, we show that the functional effects of point mutations along each M4 or at homologous positions in M4 from different subunits are additive so that multiple simultaneous mutations add together leading to substantial

^{*} For correspondence: John E. Baenziger, John.Baenziger@uottawa.ca.



Figure 1. The M4 lipid sensors from each subunit of the nAChR are the most lipid-exposed TMD a-helices. Homology model of the human adult muscle nAChR based on the 2.7 Å resolution *Torpedo* nAChR structure (Protein Data Bank: 6UWZ). *A*, side view of the full model colored by domain with agonist-binding site residues (α Trp149) and channel gate residues (9' and 13') is shown as *spheres* colored *cyan* and *tan*, respectively. *B*, zoomed in view of a single subunit with the MA α -helix removed for clarity. The M4 α -helix, post-M4, and the Cys-loop are shown in *red*, *blue*, and *green*, respectively. *C*, top-down view of the TMD with M4 helices from each subunit colored *red*. nAChR, nicotinic acetylcholine receptor; TMD, transmembrane domain.

functional effects. Finally, we show that the functional consequences of some M4 mutations are dependent upon the cellular context. Our data predict that lipid sensing in the muscle nAChR *via* M4 is governed by cumulative changes in multiple interactions at the M4–M1/M3 interface that add up to substantive functional effects, as opposed to the alteration of specific interactions that play a critical role in channel function.

Results

Alanine scan of α M4, β M4, δ M4, and ε M4

The M4 α -helix from each of the four nAChR subunits is composed predominantly of aliphatic residues interspersed with neutral hydrogen bonding, charged and aromatic residues that could each form interactions with side chains on M1/M3 or with lipids that are essential to channel function and that could thus play a role in lipid sensing. To identify functionally important interactions, we generated an alanine mutation of each residue on M4 from the α , β , δ , and ε subunits. We were generous in our definition of M4 and included several residues in flanking regions, including many in post-M4. We examined the functional consequences by expressing each M4-mutated subunit along with nonmutated subunits in *Xenopus* oocytes. The concentration response of each to acetylcholine (ACh) was measured using two-electrode voltage clamp (TEVC) electrophysiology.

Of the 155 generated alanine mutants (36 in α , 40 in β , 37 in δ , and 42 in ε), all but one (ε M430A) functionally expressed, with each of the functional mutants leading to robust inward currents whose peak amplitudes increase in an ACh concentration–dependent manner (Fig. 2). Derived EC₅₀/pEC₅₀ values for those mutations that led to statistically significant changes in function are summarized in Table 1, with the EC₅₀/pEC₅₀ values for all mutations presented in Tables S1–S4. Note that each EC₅₀/pEC₅₀ value reflects a weighted ensemble of all the rate constants associated with both agonist binding/dissociation and channel opening/closing, although the measured values can be influenced by the rates of desensitization. We assume that the changes in the





Figure 2. Functional effects of alanine mutations to residues within each M4 α-helix of the nAChR. Representative whole-cell two-electrode voltage clamp traces are shown for WT and the largest function-altering Ala mutants in the M4 α-helices of each subunit. Normalized concentration response curves for the selected mutants are shown in the *bottom right*. nAChR, nicotinic acetylcholine receptor.

measured EC_{50}/pEC_{50} values reflect primarily changes in the channel opening/closing rate constants as (1) the studied mutations are distant from the agonist-binding site and thus unlikely to directly alter agonist binding/dissociation (11, 27) and (2) although only minor changes in the rates of desensitization are observed (Fig. 2), the reported changes in EC_{50} , or lack thereof, are not correlated with altered desensitization rates. A left shift in the concentration response leading to a

decrease in EC_{50} reflects a gain of function, whereas a right shift leading to an increase in EC_{50} reflects a loss of function.

As was observed previously with alanine substitutions in α M4 (26), alanine substitutions in β M4, δ M4, and ϵ M4 led to a mix of gain-of-function and loss-of-function phenotypes, with most of the function-altering mutations located along the M4–M1/M3 interface (Fig. S1). The proportion of mutations leading to statistically significant changes in function is slightly

Table 1

Alanine mutations in M4 of each subunit that led to statistically significant changes in pEC₅₀

| | | Dose response ^{a,b} | | | | |
|---------------------|-----------------------|---|------------------------------------|----|-------------------------------|--|
| | | | | | $\left[EC_{50}(Mut) \right]$ | |
| Mutant | EC ₅₀ (µM) | pEC ₅₀ (M) | Hill slope | n | EC ₅₀ (WT) | |
| WT | 7.61 | 5.12 ± 0.07 | 1.70 ± 0.47 | 50 | _ | |
| α subunit | 10.0 | | | 10 | 1.07 | |
| αL433A | 10.3 | 4.99 ± 0.04 | 1.93 ± 0.14 | 12 | 1.35 | |
| αR429A | 40.0 | 4.41 ± 0.11 | 1.09 ± 0.12 | 10 | 5.25 | |
| αF426A | 2.02 | 5.71 ± 0.14 | 1.80 ± 0.76 | 11 | 0.27 | |
| αV425A | 4.30 | 5.37 ± 0.05 | 1.89 ± 0.28 | 10 | 0.57 | |
| αL423A «T422A | 5.80 | 5.24 ± 0.07 | 2.54 ± 0.66 | 10 | 0.76 | |
| aG421A | 51.2 | 4.52 ± 0.15 | 1.40 ± 0.12 1.96 ± 0.26 | 10 | 4.10 | |
| aI420A | 5 97 | 5.00 ± 0.05 5.23 ± 0.07 | 1.90 ± 0.20 2.71 ± 0.33 | 10 | 0.78 | |
| aC418A | 10.6 | 4.99 ± 0.07 | 1.82 ± 0.33 | 9 | 1 40 | |
| aM415A | 12.5 | 4.92 ± 0.13 | 1.62 ± 0.00 1.61 ± 0.27 | 10 | 1.65 | |
| αF414A | 4.47 | 5.36 ± 0.09 | 1.76 ± 0.34 | 10 | 0.59 | |
| αL411A | 9.86 | 5.02 ± 0.10 | 2.35 ± 0.40 | 13 | 1.30 | |
| αL410A | 5.21 | 5.27 ± 0.06 | 2.06 ± 0.59 | 21 | 0.68 | |
| αH408A | 10.1 | 5.00 ± 0.05 | 1.80 ± 0.27 | 10 | 1.33 | |
| αD407A | 4.97 | 5.31 ± 0.04 | 3.12 ± 0.78 | 11 | 0.65 | |
| αY401A | 9.86 | 5.01 ± 0.03 | 1.75 ± 0.48 | 11 | 1.30 | |
| αK400A | 12.9 | 4.90 ± 0.09 | 1.89 ± 0.63 | 15 | 1.70 | |
| β subunit | | | | | | |
| βP476A | 4.98 | 5.33 ± 0.20 | 1.49 ± 0.34 | 13 | 0.65 | |
| βD475A | 4.15 | 5.39 ± 0.11 | 1.27 ± 0.31 | 8 | 0.54 | |
| βH470A | 13.0 | 4.90 ± 0.11 | 1.24 ± 0.19 | 13 | 1.71 | |
| βD466A | 5.08 | 5.31 ± 0.14 | 1.57 ± 0.48 | 11 | 0.67 | |
| βI463A | 3.67 | $5.44 \pm 0.16^{\circ}$ | 1.78 ± 0.11 | 8 | 0.48 | |
| βG459A | 14.4 | 4.90 ± 0.28 | 1.12 ± 0.30 | 10 | 1.89 | |
| βS457A | 13.2 | 4.93 ± 0.22 | 1.10 ± 0.24 | 11 | 1.74 | |
| β1453A | 4.57 | 5.36 ± 0.12 | 1.46 ± 0.24 | 8 | 0.60 | |
| βW450A | 12.7 | 4.94 ± 0.19 | 1.27 ± 0.20 | 14 | 1.66 | |
| BL449A | 15.9 | 4.82 ± 0.15 | 1.45 ± 0.19 | 8 | 2.09 | |
| рг448А рудда д | 4.30 | 5.38 ± 0.15 | 1.03 ± 0.48 1.80 ± 0.20 | 8 | 0.57 | |
| pv444A S cubunit | 2.22 | 5.00 ± 0.07 | 1.89 ± 0.50 | 11 | 0.29 | |
| SD479A | 4 72 | 5.24 ± 0.11^{b} | 1.42 ± 0.56 | 7 | 0.62 | |
| δD477Δ | 4.72 | 4.94 ± 0.09^{b} | 1.45 ± 0.50 1.26 ± 0.14 | 8 | 1.51 | |
| δG471A | 14.1 | 4.86 ± 0.11^{b} | 1.20 ± 0.14 1.57 ± 0.25 | 4 | 1.51 | |
| δΙ 469Α | 5 13 | 5.30 ± 0.09^{b} | 1.57 ± 0.25 1.71 ± 0.38 | 9 | 0.67 | |
| δ1467Α | 4.63 | 5.30 ± 0.07^{b} | 1.71 ± 0.50 1.91 ± 0.79 | 7 | 0.61 | |
| δW466A | 5.49 | 5.28 ± 0.14^{b} | 1.57 ± 0.27 | 8 | 0.72 | |
| δG463A | 4.88 | $5.32 \pm 0.10^{\rm b}$ | 1.71 ± 0.38 | 8 | 0.64 | |
| δP458A | 4.08 | 5.40 ± 0.09^{b} | 2.06 ± 0.75 | 7 | 0.54 | |
| δV456A | 5.06 | 5.33 ± 0.19^{b} | 1.58 ± 0.41 | 8 | 0.66 | |
| δC452A | 4.86 | 5.32 ± 0.07^{b} | 1.56 ± 0.16 | 11 | 0.64 | |
| δR450A | 5.15 | 5.29 ± 0.04^{b} | 1.72 ± 0.17 | 7 | 0.68 | |
| δD449A | 5.03 | 5.34 ± 0.20^{b} | 2.00 ± 0.19 | 8 | 0.66 | |
| δV444A | 4.35 | 5.36 ± 0.03^{b} | 2.02 ± 0.17 | 8 | 0.57 | |
| ε subunit | | | | | | |
| εI471A | 15.5 | 4.81 ± 0.07^{b} | 1.61 ± 0.24 | 10 | 2.04 | |
| εC470A | 13.4 | $4.88 \pm 0.05^{\text{b}}$ | 1.54 ± 0.08 | 12 | 1.76 | |
| εP463A | 12.1 | $4.93 \pm 0.08^{\text{D}}$ | 1.77 ± 0.10 | 9 | 1.59 | |
| εY458A | 5.10 | $5.30 \pm 0.07^{\text{b}}$ | 1.43 ± 0.20 | 8 | 0.67 | |
| εF454A | 3.90 | $5.42 \pm 0.10^{\circ}$ | 1.80 ± 0.25 | 8 | 0.51 | |
| ε1453A | 4.50 | $5.35 \pm 0.06^{\circ}$ | 1.83 ± 0.27 | 8 | 0.59 | |
| εG449A | 5.62 | $5.26 \pm 0.12^{\circ}$ | 1.54 ± 0.52 | 9 | 0.74 | |
| EC438A | 10.1 | $5.00 \pm 0.06^{\circ}$ | 1.67 ± 0.20 | 9 | 1.33 | |
| EN436A | 12.9 | $4.90 \pm 0.09^{\circ}$ | 1.6 ± 0.22 | 11 | 1.70 | |
| EG431A | 10.6 | 4.99 ± 0.11 ⁻ | 1.60 ± 0.17 | 8 | 1.40 | |
| eW430A | ino current | $\frac{1}{5}25 + 0.06^{b}$ | $\frac{-}{156 \pm 0.19}$ | ð | - 0.74 | |
| eW/A27 A | 5.02 5.05 | 5.25 ± 0.00 5.25 ± 0.14 ^b | 1.30 ± 0.19 1.37 ± 0.20 | 0 | 0.74 | |
| εW42/A | 5.85 | 5.25 ± 0.14 | 1.37 ± 0.39 | 9 | 0.77 | |

^{*a*} Measurements performed 1 to 4 days after cRNA injection (V_{hold} ranging from -20 to -80 mV). Error values are represented as standard deviation.

p < 0.001 relative to WT via one-way ANOVA followed by Dunnet's post hoc test.

^c No significant current observed up to 4 days after cRNA injection.

lower in β , δ , or ε than in α , which is present twice per pentamer (17 of 36 in α [47%]; 12 of 40 in β [30%]; 13 of 37 in δ [35%]; and 12 of 42 [29%] in ε). Furthermore, only four of the 119 mutations in β , δ , and ε combined led to more than a twofold change in function (BV444A, BL449A, BI463A, and ɛI471A) with the largest being a 3.4-fold gain of function with $\beta V444A.$ In contrast, three of 36 mutants do so in the α subunit, with these three mutants leading to larger 4.1-fold, 3.8-fold, and 5.3-fold changes in function (aT422A, aF426A, and α R429A, respectively). The detected changes in EC₅₀ values show that there are interactions at both the M4-M1/ M3 and M4-lipid interface that influence channel function. On the other hand, the absence of dramatic changes in the EC₅₀ values (except for ɛM430A, see later) suggests that there are no specific interactions at either interface that are critical for channel gating.

The data exhibit several intriguing trends that allow us to glean some insight into the functional roles played by the M4 α -helix from each of the different subunits:

First, of the four alanine mutations in $\beta/\delta/\epsilon$ that altered function by more than twofold, three of these are in β M4 (β V444A, β L449A, and β I463A) (Fig. 3). In contrast, although δ M4 has a higher proportion of statistically significant function altering alanine mutants than β M4, none produced more



- aM4 399 WKYVAMVMDHILLGVFMLVCIIGTLAVFAGRLIELNQQG
- βM4 437 WQFVAMVVDRLFLWTFIIFTSVGTLVIFLDATYHLPPPDPFP
- δM4 441 WNRVARTVDRLCLFVVTPVMVVGTAWIFLQGVYNQPPPQPFPGDPYSYNVQDKRFI
- εM4 427 WVRMGNALDNICFWAALVLFSVGSSLIFLGAYFNRVPDLPYAPCIQP

Figure 3. Position of residues that cause significant changes in function when mutated to Ala. Zoomed in views of each subunit's TMD with residues from M4 that significantly altered the EC₅₀ when mutated to Ala shown as *sticks* and colored according to residue type: aliphatic, *tan*; aromatic, *yellow*; polar/ hydrogen bonding, *green*; negative, *red*; and positive, *blue*. A sequence alignment of M4 α-helices from each subunits of the human adult nAChR is shown at the *bottom* with residues colored according to residue type (aliphatic, *black*; aromatic, *yellow*; polar/hydrogen bonding, *green*; negative, *red*; and positive, *blue*) with post-M4 highlighted in *gray*. nAChR, nicotinic acetylcholine receptor; TMD, transmembrane domain.

than a twofold change of function. Furthermore, alanine mutations in ϵ M4 led to relatively few statistically significant changes in function, although ϵ I471A, which is in post-M4, alters the EC₅₀ approximately twofold. The relatively large changes in function observed with the three alanine mutations in β M4 suggest that specific regions along the β M4– β M1/ β M3 interface are functionally important. This finding was unexpected given that β is a structural subunit that is not directly involved in agonist binding. In addition, the four TMD α -helices in the β subunit undergo the lowest amplitude motions upon agonist binding (16, 17).

Second, none of the alanine mutations of residues in β , δ , and ε that align with those residues in α M4, whose mutation to alanine led to relatively large changes in function, have substantial effects on the measured EC₅₀ values. Specifically, aT422A, aF426A, and aR429A led to 4.1-fold, 3.8-fold, and 5.3-fold changes in the recorded EC₅₀ values, as noted previously. The equivalent residues in the other three subunits are BT460, BF464, and BA467; ST464, SF468, and SG471; and ε S450, ε F454, and ε A457. Of the alanine mutations generated for these equivalent residues, only ε F454A and δ G471A led to statistically significant changes in the EC50 values, although the effects on function in both cases are less than twofold. These data show that identical changes in the structure of the M4 α -helix from different subunits lead to different effects on function. The M4 α -helix from the α , β , δ , and ε subunits thus each plays a subtly different functional role.

Third, ε M430A is the only mutant that did not functionally express (Fig. 3). ε Met430 extends toward ε MX into a hydrophobic pocket formed by residues on ε M3, ε M4, and ε MX. ε MX is implicated in the assembly/cell surface trafficking of the muscle nAChR, with mutations in ε MX reducing cell surface expression leading to CMS (28). Residues in M4 that project toward MX may play a particularly important role in nAChR expression.

Finally, we were surprised to see that the ε C470A mutant led to robust ACh-induced currents that are comparable in magnitude to those observed with the WT nAChR. In contrast, ε C470A, ε C470S, and a deletion mutation at ε C470 each inhibits cell surface expression of the nAChR in human embryonic kidney 293T (HEK293T) cells, with low expression of the latter in humans leading to CMS (29). It has been suggested that the sulfhydryl side chain of ε Cys470 is critical for folding and expression. Our data show that the side chain of ε C470 is not intrinsically required for folding. It appears that the lipid environment of an oocyte supports folding of the ε C470A mutant, whereas the lipid environments of HEK293T cells and muscle cells do not (see later).

Role of post-M4 in channel function

Post-M4 is required for optimal expression/function in some pLGICs but not in others (19–24). In our alanine scans, we observed that only nine of 51 mutations in post-M4 led to statistically significant changes in function (α L433A, β H470A, β D475A, β P476A, δ P477A, δ P478A, ϵ P463A, ϵ C470A, and

εI471A), but none of these altered function by more than approximately twofold.

Although the subtle effects of the single alanine mutants imply that interactions between post-M4 and the remainder of the nAChR are not critical for folding/function, we explored this possibility further by generating a series of C-terminal deletions in each subunit. In the α subunit, deletion of up to nine residues ($\alpha \Delta 9$) led to only a twofold or less loss of function, with the deletion of additional residues extending into the M4 α -helix ($\alpha\Delta 12$) eventually leading to a loss of functional expression (26) (Fig. 4 and Table 2). Similarly, deleting up to eight residues in β M4 and ϵ M4, or 12 residues in δ M4, had little to no effect, with further deletions of up to 13 residues in β M4 and 24 residues in either δ M4 or ϵ M4 leading to subtle loss of function (β and δ) or gain of function (ε). Surprisingly, the 24-residue deletion in δ restored WT activity, whereas the 15- and 24-residue deletions in β and ε , respectively, led to gain of function ($\varepsilon \Delta 24$ led to a relatively large 6.3fold gain of function). These results show that the post-M4 region is not important in the folding or function of the adult muscle nAChR.

Aromatic residues at the M4-M1/M3 interface

Aromatic residues play a critical role at the M4–M1/M3 interface in many pLGICs. Some pLGICs, such as the 5-HT₃AR, the α 1 GlyR, the α 7 nAChR, the ρ 1 GABA_AR, and the prokaryote *Gloebacter* ligand-gated ion channel (GLIC), exhibit an extensive network of interacting aromatic residues that drives M4–M1/M3 interactions to facilitate folding and possibly function (20, 23, 30–33). In contrast, fewer aromatic residues at this interface in ELIC are thought to sterically prevent tight interactions between M4 and M1/M3, thus creating a more malleable M4–M1/M3 interface that is potentially more sensitive to modulation by factors, such as the surrounding lipid environment (34). As in ELIC, the muscle nAChR exhibits relatively few aromatic residues likely leading to a malleable M4–M1/M3 interface that might underlie its exquisite lipid sensitivity (31).

We mutated every aromatic residue at this interface in each subunit of the nAChR to alanine and tested the effects of each on channel function (Fig. 5 and Table 3). In general, we found that aromatic to alanine substitutions in the α , β , δ , and ε subunits led to either no effect or subtle gains in function. These data suggest that bulky aromatic side chains sterically prevent optimal M4–M1/M3 interactions, with the reduction in size possibly promoting tighter interactions to enhance channel function.

aC418W-induced potentiation of channel function

To compare further how similar changes in the structure of the M4 α -helix from different subunits influence channel function, we focused on a site where the introduction of a tryptophan in the α subunit, α C418W, potentiates channel function 16- to 25-fold leading to a slow channel CMS (13) (Table 4). Mutant cycles show that the α C418W-induced potentiation is driven primarily by a new interaction that forms



Figure 4. Location of C-terminal deletions in each subunit. Side views of each subunit are shown with M4 helices and post-M4 semitransparent. Black spheres denote α-carbons for each deletion mutation.

between the introduced tryptophan, α Trp418, and an adjacent residue on α M1, α Ser226, with this interaction likely stabilizing the open state (35). The importance of this interaction in α C418W-induced potentiation is demonstrated by the fact that α C418W only potentiates channel function 3.4-fold when the tryptophan is introduced onto the α S226A background.

Given that β , δ , and ε each contains a homologous residue to α Ser226 (β Thr237, δ Ser240, and ε Ser235) on M1, we expected a similar degree of potentiation upon mutation of the αCys418 equivalent residue in each subunit (βThr456, δMet460, and εPhe446) to tryptophan. In contrast, tryptophan substitutions in β, δ, and ε, (βT456W, δM460W, and εF446W) led to only a 1.7-fold gain, a 1.6-fold loss, and a 1.8-fold gain of function, respectively, consistent with what is observed in the *Torpedo* nAChR (36–38). Furthermore, the βT237A mutation on M1 had no effect on the magnitude of the βT456Winduced response implying that the introduced tryptophan, βT456W, does not interact with βT237 to potentiate channel

Table 2

Effects of M4 C-terminal deletions on nAChR function and expression

| Deletion(s) EC ₃₀ (µM) pEC ₃₀ (M) Hill slope n a suburit a a a a b b b b b b b b b b b b b c b c b c b c b c b c b c c c b c <td< th=""><th colspan="7">Dose response^a</th></td<> | Dose response ^a | | | | | | |
|---|--|-------------------------|--------------------------------|------------------------------------|--------|--|--|
| a subunit $VT:LAVFAGRIJELNQQG 7.41 512 ± 0.07 1.70 ± 0.47 50 \Lambda I:LAVFAGRIJELNQQ 6.86 517 ± 0.06 2.66 ± 0.67 9 \Lambda I:LAVFAGRIJELNQQ 6.86 517 ± 0.06 2.66 ± 0.67 9 \Lambda I:LAVFAGRIJELNQQ 6.87 5.20 ± 0.07 2.26 ± 0.38 8 \Lambda I:LAVFAGRIJELN 7.14 515 \pm 0.07 2.26 ± 0.38 8 \Lambda I:LAVFAGRIJEL 12.14 515 \pm 0.07 2.26 ± 0.38 18 \Lambda I:LAVFAGRIJE 12.14 1.18 4.93 ± 0.04^{5} 1.65 ± 0.33 10 \Lambda I:LAVFAGRIJE 12.3 4.91 \pm 0.04^{5} 1.65 \pm 0.33 10 \Lambda I:LAVFAGRIJ 12.3 4.91 \pm 0.04^{5} 1.65 \pm 0.33 10 \Lambda I:LAVFAGRIJ 12.3 4.91 \pm 0.04^{5} 1.05 \pm 0.25 10 \ 0.47LAVFAGRI 14.17 4.88 \pm 0.07^{5} 1.16 \pm 0.15 10 \ 0.48LAVFAGRI 14.7 4.88 \pm 0.06^{5} 1.54 \pm 0.15 10 \ 0.49LAVFAG 14.47 4.88 \pm 0.08^{5} 1.177 \pm 0.35 10 \ 0.41LAVF 12.14 4.68 \pm 0.08^{5} 1.177 \pm 0.35 10 \ 0.11LAVF 2.30 4.65 \pm 0.09^{5} 1.69 \pm 0.36 10 \ 0.11LAVF 2.30 4.65 \pm 0.09^{5} 1.69 \pm 0.36 10 \ 0.12LAV VAG 14.49 V No current 8 \ 0.12LAV VAG 1.14 VAR 14.19 VPDPFP 7.50 1.24 0.07 1.70 \pm 0.47 50 \ 0.12LAV 1.10 ATVHLIPPDPFP 7.50 1.00 0.5 1.61 \pm 0.15 10 \ 0.13 10 \ 0.48LVHEDATVHLIPPDPFP 7.50 1.00 0.5 1.61 \pm 0.15 10 \ 0.16 1.79 \pm 0.30 \ 0.15 \pm 0.07 1.70 \pm 0.47 50 \ 0.16LVHEDATVHLIPPDPF 7.50 1.00 0.5 1.61 \pm 0.15 \ 0.175 \pm 0.13 10 \ 0.48LVHEDATVHLIPPDPF 7.50 1.00 0.5 1.61 \pm 0.15 \ 0.175 \pm 0.13 \ 0.10 \ 0.48LVHEDATVHLIPPDP 7.50 0.5 1.61 \pm 0.15 \ 0.175 \pm 0.13 \ 0.15 \ 0.175 \pm 0.13 \ 0.15 \$ | Deletion(s) | EC ₅₀ (µM) | pEC ₅₀ (M) | Hill slope | n | | |
| WT:LAVFAGRUELNQQG 7.61 5.12 ± 0.07 1.70 ± 0.47 50 AL:LAVFAGRUELNQQ 6.86 5.17 ± 0.06 2.66 ± 0.67 9 AL:LAVFAGRUELNQ 6.37 5.20 ± 0.07 2.26 ± 0.54 9 AL:LAVFAGRUELN 7.14 5.15 ± 0.07 2.36 ± 0.38 8 Ad:LAVFAGRUEL 8.49 5.08 ± 0.07 2.13 ± 0.44 8 Ad:LAVFAGRUEN 12.3 4.91 ± 0.04° 1.55 ± 0.01 1.00 AS:LAVFAGRUE 12.7 4.90 ± 0.06° 1.54 ± 0.15 1.00 AS:LAVFAGR 14.7 4.84 ± 0.00° 1.46 ± 0.29 1.00 AS:LAVFAGR 14.7 4.84 ± 0.00° 1.46 ± 0.29 1.00 AD:LAVFAG 14.9 4.83 ± 0.08° 1.37 ± 0.35 1.00 AD:LAVFAG 14.9 4.83 ± 0.08° 1.35 ± 0.12 1.00 AD:LAVFAG 14.9 4.83 ± 0.08° 1.35 ± 0.12 1.00 AD:LAVFAG 14.9 4.85 ± 0.09° 1.59 ± 0.08 1.46 1.01 ± 0.135 ± 0.12 1.00 AD:LAVFLDATYHLPPPDF 9.65 5.02 ± 0.07 1.01 ± 0.47 | α subunit | | | | | | |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | WT:LAVFAGRLIELNQQG | 7.61 | 5.12 ± 0.07 | 1.70 ± 0.47 | 50 | | |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | Δ1:LAVFAGRLIELNQQ | 6.86 | 5.17 ± 0.06 | 2.66 ± 0.67 | 9 | | |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | Δ2:LAVFAGRLIELNQ | 6.37 | 5.20 ± 0.07 | 2.62 ± 0.54 | 9 | | |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | Δ3:LAVFAGRLIELN | 7.14 | 5.15 ± 0.07 | 2.36 ± 0.38 | 8 | | |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | $\Delta 4$:LAVFAGRLIEL | 8.49 | 5.08 ± 0.07 | 2.13 ± 0.44 | 8 | | |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | Δ5:LAVFAGRLIE | 11.8 | 4.93 ± 0.04^{b} | 1.65 ± 0.33 | 10 | | |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | Δ6:LAVFAGRLI | 12.3 | 4.91 ± 0.04^{b} | 1.59 ± 0.25 | 10 | | |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | Δ7:LAVFAGRL | 12.7 | 4.90 ± 0.06^{b} | 1.54 ± 0.15 | 10 | | |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | Δ8:LAVFAGR | 14.7 | 4.84 ± 0.07^{b} | 1.46 ± 0.29 | 10 | | |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | Δ9:LAVFAG | 14.9 | 4.83 ± 0.08^{b} | 1.77 ± 0.35 | 10 | | |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | $\Delta 10: \dots LAVFA$ | 21.4 | 4.68 ± 0.08^{b} | 1.35 ± 0.12 | 10 | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | Λ11:LAVF | 23.0 | 4.65 ± 0.09^{b} | 1.69 ± 0.36 | 10 | | |
| | Δ12:LAV | No current ^c | | | | | |
| WT:LVIFLDATYHLPPPDPF7.61 512 ± 0.07 1.70 ± 0.47 50 $\Delta1:$ LVIFLDATYHLPPPDPF9.77 5.02 ± 0.09 1.59 ± 0.08 13 $\Delta2:$ LVIFLDATYHLPPPDP9.65 5.02 ± 0.05 1.61 ± 0.11 11 $\Delta3:$ LVIFLDATYHLPPPDP9.04 5.05 ± 0.08 1.46 ± 0.19 12 $\Delta4:$ LVIFLDATYHLPPP7.00 5.13 ± 0.15 1.75 ± 0.13 10 $\Delta4:$ LVIFLDATYHLPPP7.00 5.13 ± 0.15 1.75 ± 0.20 7 $\Delta10:$ LVIFLDATY 11.6 4.94 ± 0.08^{b} 1.45 ± 0.21 9 $\Delta13:$ LVIFLDATY 15.0 4.84 ± 0.14^{b} 1.32 ± 0.30 11 $\Delta15:$ LVIFL 15.0 4.84 ± 0.14^{b} 1.32 ± 0.30 11 $\Delta15:$ LVIFL 15.0 4.84 ± 0.14^{b} 1.32 ± 0.30 11 $\Delta15:$ LVIFLQGVYNQPPQPFPGDPYSYNVQDKRF 9.20 5.04 ± 0.07 1.70 ± 0.47 50 $\Delta1:$ WIFLQGVYNQPPQPFPGDPYSYNVQDKR 7.72 5.13 ± 0.13 1.71 ± 0.13 8 $\Delta4:$ WIFLQGVYNQPPQPFPGDPYSYNVQDK 5.95 5.24 ± 0.14 1.55 ± 0.10 8 $\Delta4:$ WIFLQGVYNQPPQPFPGDPYSYNVQDK 5.15 4.88 5.06 ± 0.07 1.50 ± 0.33 9 $\Delta12:$ WIFLQGVYNQPPQPFPGDPYSYNVQDK 5.15 4.84 ± 0.12^{b} 1.51 ± 0.20 8 $\Delta4:$ WIFLQGVYNQPPQPFPGDPYSYNVQDK 5.15 4.84 ± 0.07^{b} 1.65 ± 0.01 8 $\Delta4:$ <td>ß subunit</td> <td>rio current</td> <td></td> <td></td> <td>Ũ</td> | ß subunit | rio current | | | Ũ | | |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | WT:LVIFLDATYHLPPPDPFP | 7.61 | 5.12 ± 0.07 | 1.70 ± 0.47 | 50 | | |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | Λ_1 · IVIFIDATYHI PPPDPF | 977 | 5.02 ± 0.09 | 159 ± 0.08 | 13 | | |
| A3:LVIFLDATYHLIPPD 5.02 5.02 6.03 1.46 ± 0.17 11 A4:LVIFLDATYHLIPPD 9.04 5.05 ± 0.03 1.46 ± 0.17 12 A4:LVIFLDATYHLPPD 7.00 5.13 ± 0.15 1.75 ± 0.13 10 A8:LVIFLDATYH 8.36 5.10 ± 0.16 1.79 ± 0.20 7 A10:LVIFLDATYH 8.36 5.01 ± 0.16 1.79 ± 0.20 7 A11:LVIFL 11.6 4.94 ± 0.04^{b} 1.32 ± 0.30 11 $\Delta15:LVI$ 4.25 5.33 ± 0.15^{b} 1.87 ± 0.20 9 δ submit $WT:WIFLQGVYNQPPPQPFPGDPYSYNVQDKRF 9.20 5.04 \pm 0.07 1.46 \pm 0.20 8 \Delta2:WIFLQGVYNQPPPQPFPGDPYSYNVQDKR 7.72 5.13 \pm 0.13 1.71 \pm 0.13 8 \Delta3:WIFLQGVYNQPPPQPFPGDPYSYNVQDK 5.95 5.24 \pm 0.14 1.55 \pm 0.10 8 \Delta4:WIFLQGVYNQPPPQPFPGDPYSYNVQDK 5.95 5.24 \pm 0.07 1.60 \pm 0.21 8 \Delta4:WIFLQGYYNQPPPQPFPGDPYSYNVQDK 5.95 5.24 \pm 0.07 1.60 \pm 0.21 8 \Delta4:WIFLQGYYNQPPPQPFPGDPYSYNVQDK $ | | 9.65 | 5.02 ± 0.05 | 1.61 ± 0.11 | 11 | | |
| A4:LVIFLDATYHUIPP 7.00 5.13 ± 0.05 1.75 ± 0.13 10 A4:LVIFLDATYH 8.36 5.10 ± 0.16 1.79 ± 0.20 7 A10:LVIFLDATYH 8.36 5.10 ± 0.16 1.79 ± 0.20 7 A10:LVIFLDAT 11.6 4.94 ± 0.08 ⁶ 1.45 ± 0.21 9 A13:LVIFL 15.0 4.84 ± 0.14 ⁶ 1.32 ± 0.30 11 A15:LVI 4.25 5.33 ± 0.15 ⁶ 1.87 ± 0.20 9 δ subunit 4.25 5.33 ± 0.15 ⁷ 1.87 ± 0.20 9 MT:WIFLQGVYNQPPPQPFFGDPYSNVQDKRF 9.20 5.04 ± 0.07 1.46 ± 0.20 8 A2:WIFLQGVYNQPPPQPFFGDPYSNVQDKR 7.72 5.13 ± 0.13 1.71 ± 0.13 8 A3:WIFLQGVYNQPPPQPFFGDPYSNVQD 5.95 5.24 ± 0.14 1.55 ± 0.10 8 A4:WIFLQGYNQPPPPPFFGDPYSNVQD 8.11 5.10 ± 0.07 1.60 ± 0.21 8 A4:WIFLQGYNQPPPPPFFGDPYSNVQD 8.11 5.10 ± 0.07 1.50 ± 0.33 9 A12:WIFLQGYNQPPPPFFGDPYSNVQD 8.11 5.10 ± 0.07 1.50 ± 0.33 9 A12:WIFLQGYNQPPPPFFGDPYSNVQD 8.21 | A3: I VIELDATYHI PPPD | 9.03 | 5.02 ± 0.03 | 1.01 ± 0.11 1.46 ± 0.19 | 12 | | |
| A8:LVIELDAT HILLITT 7.00 5.13 ± 0.13 1.79 ± 0.03 17 A8:LVIELDAT HILLITT 11.6 4.94 ± 0.08 ⁶ 1.45 ± 0.21 9 A10:LVIEL 15.0 4.84 ± 0.14 ⁶ 1.32 ± 0.30 11 A15:LVI 4.25 5.33 ± 0.15 ⁶ 1.87 ± 0.20 9 Subunit 4.25 5.33 ± 0.15 ⁶ 1.87 ± 0.20 9 MT:WIFLQGVYNQPPPQPFPGDPYSYNVQDKRF 9.20 5.04 ± 0.07 1.70 ± 0.47 50 A1:WIFLQGVYNQPPPQPFPGDPYSYNVQDKR 7.72 5.13 ± 0.13 1.71 ± 0.13 8 A2:WIFLQGVYNQPPPQPFPGDPYSYNVQDK 5.95 5.24 ± 0.14 1.55 ± 0.10 8 A3:WIFLQGVYNQPPPQPFPGDPYSYNVQDK 5.95 5.04 ± 0.07 1.60 ± 0.21 8 A4:WIFLQGVYNQPPPQFPFGDPYSYNVQDK 5.95 5.04 ± 0.07 1.60 ± 0.21 8 A4:WIFLQGVYNQPPPQFPFGD 9.90 5.01 ± 0.06 1.32 ± 0.18 8 A20:WIFLQGVYNQPPPQFPFGD 9.90 5.01 ± 0.06 1.32 ± 0.18 8 A21:WIFLQGVYNQPPPQPFFGD 9.90 5.01 ± 0.06 1.32 ± 0.13 3 A22:WIFLQGVYNQPPPQPFFD | ΔA_{ℓ} I VIELDAT THEIT D | 7.00 | 5.05 ± 0.08 5.13 + 0.15 | 1.70 ± 0.17 1.75 ± 0.13 | 10 | | |
| AlbLVIELDAT 11.6 4.94 \pm 0.08b 1.45 \pm 0.21 9 Al3LVIEL 15.0 4.84 \pm 0.14b 1.32 \pm 0.30 11 Al5LVI 15.0 4.84 \pm 0.14b 1.32 \pm 0.30 11 Al5LVI 15.0 4.84 \pm 0.14b 1.32 \pm 0.30 11 Al5LVI 4.25 5.33 \pm 0.15b 1.87 \pm 0.20 9 δ subunit | $\Delta \mathbf{x}$. IVIELDATTHEFT | 8 36 | 5.13 ± 0.13 5.10 + 0.16 | 1.75 ± 0.15 1.79 ± 0.20 | 10 | | |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | $\Delta 0$, LVIELDAT | 11.6 | 4.94 ± 0.08^{b} | 1.77 ± 0.20 1.45 ± 0.21 | , 0 | | |
| A15:VIPL1.50 $4.42 \pm 0.14^{\circ}$ 1.52 ± 0.30 11A15:LVI4.25 $5.33 \pm 0.15^{\circ}$ 1.87 ± 0.20 9 δ subunitWIFLQGYYNQPPQPFPGDPYSYNVQDKRF7.61 5.12 ± 0.07 1.70 ± 0.47 50A1:WIFLQGYYNQPPPQPFPGDPYSYNVQDKR7.72 5.13 ± 0.13 1.71 ± 0.13 8A2:WIFLQGYYNQPPPQPFPGDPYSYNVQDK5.95 5.24 ± 0.14 1.55 ± 0.10 8A4:WIFLQGYYNQPPPQFPGDPYSYNVQDK5.95 5.24 ± 0.14 1.55 ± 0.10 8A4:WIFLQGYYNQPPPQFPGDPYSYNVQD8.11 5.10 ± 0.07 1.60 ± 0.21 8A8:WIFLQGYYNQPPPQFPGDPYSY8.88 5.06 ± 0.07 1.50 ± 0.33 9A12:WIFLQGYYNQPPPQFPGD9.90 5.01 ± 0.06 1.32 ± 0.18 8A20:WIFLQGVYNQPPQP14.2 $4.85 \pm 0.07^{\circ}$ 1.68 ± 0.24 8A20:WIFLQGVYNQPP15.1 $4.84 \pm 0.12^{\circ}$ 1.51 ± 0.20 8A24:WIFLQGV7.59 5.12 ± 0.01 1.55 ± 0.13 3A24:WIFLQGV7.61 5.12 ± 0.07 1.70 ± 0.47 50A24:WIF0.5 1.62 ± 0.10 8 4.22 ± 0.05 1.72 ± 0.08 8A21:SVGSSLIFLGAYFNRVPDLPYAPCIQP7.61 5.12 ± 0.07 1.70 ± 0.47 50A1:SVGSSLIFLGAYFNRVPDLPYAPCIQP7.61 5.12 ± 0.07 1.70 ± 0.47 50A2:SVGSSLIFLGAYFNRVPDLPYAPCIQP6.40 5.20 ± 0.05 | | 15.0 | 4.94 ± 0.08 | 1.45 ± 0.21 1.22 ± 0.20 | 11 | | |
| A15 V1 425 5.35 ± 0.15 1.67 ± 0.20 9 WT WIFLQGVYNQPPQPFPGDPYSYNVQDKRFI 7.61 5.12 ± 0.07 1.70 ± 0.47 50 A1: WIFLQGVYNQPPPQFPGDPYSYNVQDKRF 9.20 5.04 ± 0.07 1.46 ± 0.20 8 A2: WIFLQGVYNQPPPQFPGDPYSYNVQDKR 7.72 5.13 ± 0.13 1.71 ± 0.13 8 A3: WIFLQGVYNQPPPQFPGDPYSYNVQDK 5.95 5.24 ± 0.14 1.55 ± 0.10 8 A4: WIFLQGVYNQPPPQFPGDPYSYNVQD 8.11 5.10 ± 0.07 1.60 ± 0.21 8 A8: WIFLQGVYNQPPPQFPGDPYSYNVQD 8.11 5.01 ± 0.07 1.60 ± 0.21 8 A4: WIFLQGVYNQPPPQFPGDPYSYNVQD 8.11 5.01 ± 0.07 1.60 ± 0.21 8 A4: WIFLQGVYNQPPPQFPGD 9.90 5.01 ± 0.06 1.32 ± 0.18 8 A2: WIFLQGVYNQPPPQFPGD 16.1 4.85 ± 0.07 ^b 1.65 ± 0.13 3 A24: WIFLQGVYNQPPQ 15.1 4.84 ± 0.12 ^b 1.51 ± 0.20 8 A24: WIFLQGVYNQP 7.59 5.12 ± 0.01 1.55 ± 0.13 3 </td <td></td> <td>15.0</td> <td>4.04 ± 0.14</td> <td>1.52 ± 0.50 1.87 ± 0.20</td> <td>11</td> | | 15.0 | 4.04 ± 0.14 | 1.52 ± 0.50 1.87 ± 0.20 | 11 | | |
| 0 Subult 0 Subult 1.70 ± 0.47 50 WT:WIFLQGVYNQPPPQPFPGDPYSYNVQDKRF 9.20 5.04 ± 0.07 1.46 ± 0.20 8 Δ2:WIFLQGVYNQPPPQPFGDPYSYNVQDKR 7.72 5.13 ± 0.13 1.71 ± 0.13 8 Δ3:WIFLQGVYNQPPPQPFGDPYSYNVQDK 5.95 5.24 ± 0.14 1.55 ± 0.10 8 Δ4:WIFLQGVYNQPPPQPFGDPYSYNVQDK 5.95 5.24 ± 0.14 1.55 ± 0.13 8 Δ4:WIFLQGVYNQPPPQPFGDPYSYNVQDK 8.81 5.10 ± 0.07 1.60 ± 0.21 8 Δ8:WIFLQGVYNQPPPQPFGDPYSYNVQDK 8.88 5.06 ± 0.07 1.50 ± 0.33 9 Δ12:WIFLQGVYNQPPPQPFPGD 9.90 5.01 ± 0.06 1.32 ± 0.18 8 Δ12:WIFLQGVYNQPPPQPF 14.2 4.85 ± 0.07 ^b 1.68 ± 0.24 8 Δ20:WIFLQGVYNQPP 15.1 4.84 ± 0.12 ^b 1.51 ± 0.20 8 Δ24:WIFLQGVYNQPP 7.59 5.12 ± 0.01 1.55 ± 0.13 3 Δ24:WIFLQGVYNQPP 7.61 5.12 ± 0.01 1.55 ± 0.13 3 Δ24:WIFLQGYFNRVPDLPYAPCIQP 7.61 5.12 ± 0.07 1.70 ± 0.47 50 Δ1:SVGSSLIFLGAYFNRVPDLPYAPCIQP | Δ15;LV1 S | 4.25 | 5.55 ± 0.15 | 1.87 ± 0.20 | 9 | | |
| W1::WIFLQGV1NQPPQPFPGDP1S1NVQDKR17.515.12 ± 0.071.70 ± 0.4750A1:WIFLQGV1NQPPQPFPGDPYS1NVQDKR9.205.04 ± 0.071.46 ± 0.208A2:WIFLQGV1NQPPQPFPGDPYS1NVQDKR5.955.24 ± 0.141.55 ± 0.108A3:WIFLQGV1NQPPQPFPGDPYS1NVQDK5.955.24 ± 0.141.55 ± 0.108A4:WIFLQGV1NQPPQPFPGDPYS1NVQD8.115.10 ± 0.071.60 ± 0.218A4:WIFLQGV1NQPPQPFPGDPYSY8.885.06 ± 0.071.50 ± 0.339A12:WIFLQGVYNQPPQPFPGD9.905.01 ± 0.061.32 ± 0.188A16:WIFLQGVYNQPPQPF15.14.84 ± 0.12 ^b 1.51 ± 0.208A22:WIFLQGVYNQPPQ15.14.84 ± 0.12 ^b 1.51 ± 0.208A24:WIFLQGV7.595.12 ± 0.011.55 ± 0.133A28:WIFNo current ^c 8 ϵ subunitW1:SVGSSLIFLGAYFNRVPDLPYAPCIQ7.615.12 ± 0.071.70 ± 0.4750A1:SVGSSLIFLGAYFNRVPDLPYAPCIQ7.865.11 ± 0.051.62 ± 0.108A2:SVGSSLIFLGAYFNRVPDLPYAPCIQ8.445.08 ± 0.071.67 ± 0.119A4:SVGSSLIFLGAYFNRVPDLPYAPC8.445.08 ± 0.071.62 ± 0.108A2:SVGSSLIFLGAYFNRVPDLPYAPC8.445.08 ± 0.071.62 ± 0.108A1:SVGSSLIFLGAYFNRVPDLPYAPC8.445.08 ± 0.071.67 ± 0.119A4:SVGSSLIFLGAYFNRVPDLPYAPC8.445.08 ± 0.051.72 ± 0.088A1:SVGSSLIFLGAYFNRVPDLPYAPC <td></td> <td>7.61</td> <td>5 12 + 0.07</td> <td>1 70 + 0 47</td> <td>50</td> | | 7.61 | 5 12 + 0.07 | 1 70 + 0 47 | 50 | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | | 7.61 | 5.12 ± 0.07 | 1.70 ± 0.47 | 50 | | |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | | 9.20 | 5.04 ± 0.07 | 1.46 ± 0.20 | 8 | | |
| $\Delta 3: WIFLQGVYNQPPQPFPGDPYSYNVQD (M) 5.95 5.24 ± 0.14 1.55 ± 0.10 8 \Delta 4: WIFLQGVYNQPPPQPFPGDPYSYNVQD (M) 8.11 5.10 ± 0.07 1.60 ± 0.21 8 \Delta 8: WIFLQGVYNQPPPQPFPGDPYSY (M) 8.88 5.06 ± 0.07 1.50 ± 0.33 9 \Delta 12: WIFLQGVYNQPPPQPFPGD (M) 9.90 5.01 ± 0.06 1.32 ± 0.18 8 \Delta 16: WIFLQGVYNQPPQPPQP (M) 14.2 4.85 ± 0.07b 1.68 ± 0.24 8 \Delta 20: WIFLQGVYNQPPQPPQP 14.2 4.85 ± 0.07b 1.68 ± 0.24 8 \Delta 20: WIFLQGVYNQPPQPQP 15.1 4.84 ± 0.12b 1.51 ± 0.20 8 \Delta 24: WIFLQGV 7.59 5.12 ± 0.01 1.55 ± 0.13 3 \Delta 28: WIF (M) No currentc - - - 8 wT: SVGSSLIFLGAYFNRVPDLPYAPCIQP 7.61 5.12 ± 0.07 1.70 ± 0.47 50 \Delta 1: SVGSSLIFLGAYFNRVPDLPYAPCIQP 7.86 5.11 ± 0.05 1.62 ± 0.10 8 \Delta 2: SVGSSLIFLGAYFNRVPDLPYAPCIQ 8.44 5.08 ± 0.07 1.67 ± 0.11 9 \Delta 4: SVGSSLIFLGAYFNRVPDLPYAPC 8.444 5.08 ± 0.06 1.47 $ | | 7.72 | 5.13 ± 0.13 | 1.71 ± 0.13 | 8 | | |
| $\Delta 4:WIFLQGVYNQPPPQPFPGDPYSYNQD 8.11 5.10 \pm 0.07 1.60 \pm 0.21 8 \Delta 8:WIFLQGVYNQPPPQPFPGDPYSY 8.88 5.06 \pm 0.07 1.50 \pm 0.33 9 \Delta 12:WIFLQGVYNQPPPQPFPGD 9.90 5.01 \pm 0.06 1.32 \pm 0.18 8 \Delta 16:WIFLQGVYNQPPPQP 14.2 4.85 \pm 0.07^{b} 1.68 \pm 0.24 8 \Delta 20:WIFLQGVYNQPPQP 15.1 4.84 \pm 0.12^{b} 1.51 \pm 0.20 8 \Delta 24:WIFLQGV 7.59 5.12 \pm 0.01 1.55 \pm 0.1 3.28 \Delta 28:WIF No currentC - - 8 e subunit WT SVGSSLIFLGAYFNRVPDLPYAPCIQP 7.61 5.12 \pm 0.07 1.70 \pm 0.47 50 \Delta 1:SVGSSLIFLGAYFNRVPDLPYAPCIQP 7.61 5.12 \pm 0.07 1.62 \pm 0.10 8 \Delta 2:SVGSSLIFLGAYFNRVPDLPYAPCIQP 7.86 5.11 \pm 0.05 1.62 \pm 0.10 8 \Delta 3:SVGSSLIFLGAYFNRVPDLPYAPC 8.44 5.08 \pm 0.07 1.67 \pm 0.11 9 \Delta 4:SVGSSLIFLGAYFNRVPDLPYAPC 8.44 5.08 \pm 0.05 1.72 \pm 0.08 8 \Delta 4:SVGSSLIFLGAYFNRVPDLPYAPC $ | Δ3:WIFLQGVINQPPPQPFPGDPISINVQDK | 5.95 | 5.24 ± 0.14 | 1.55 ± 0.10 | 8 | | |
| $\Delta 8:WIFLQGVYNQPPQPFPGDPYSY 8.88 5.06 ± 0.07 1.50 ± 0.33 9 \Delta 12:WIFLQGVYNQPPPQPFGD 9.90 5.01 ± 0.06 1.32 ± 0.18 8 \Delta 16:WIFLQGVYNQPPQPP 14.2 4.85 ± 0.07b 1.68 ± 0.24 8 \Delta 20:WIFLQGVYNQP 15.1 4.84 ± 0.12b 1.51 ± 0.20 8 \Delta 24:WIFLQGV 7.59 5.12 ± 0.01 1.55 ± 0.13 3 \Delta 28:WIF No currentc - - - 8 subunit WT:SVGSSLIFLGAYFNRVPDLPYAPCIQP 7.61 5.12 ± 0.07 1.70 ± 0.47 50 \Delta 1:SVGSSLIFLGAYFNRVPDLPYAPCIQ 7.86 5.11 ± 0.05 1.62 ± 0.10 8 \Delta 2:SVGSSLIFLGAYFNRVPDLPYAPCI 6.40 5.20 ± 0.05 1.72 ± 0.08 8 \Delta 3:SVGSSLIFLGAYFNRVPDLPYAPC 8.44 5.08 ± 0.07 1.67 ± 0.11 9 \Delta 4:SVGSSLIFLGAYFNRVPDLPYAPC 8.44 5.08 ± 0.07 1.67 ± 0.11 9 \Delta 4:SVGSSLIFLGAYFNRVPDLPYAPC 8.44 5.08 ± 0.07 1.67 ± 0.11 9 \Delta 4:SVGSSLIFLGAYFNRVPDLPYAPC 8.44 5.08 ± 0.06b 1.87 ± 0.25 8<$ | Δ4:WIFLQGVYNQPPPQPFPGDPYSYNVQD | 8.11 | 5.10 ± 0.07 | 1.60 ± 0.21 | 8 | | |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | A8:WIFLQGVYNQPPPQPFPGDPYSY | 8.88 | 5.06 ± 0.07 | 1.50 ± 0.33 | 9 | | |
| $\Delta 16:WIFLQGVYNQPPQP$ 14.2 4.85 ± 0.07° 1.68 ± 0.24 8 $\Delta 20:WIFLQGVYNQP$ 15.1 4.84 ± 0.12 ^b 1.51 ± 0.20 8 $\Delta 24:WIFLQGV$ 7.59 5.12 ± 0.01 1.55 ± 0.13 3 $\Delta 28:WIF No currentc - - 8 wT:SVGSSLIFLGAYFNRVPDLPYAPCIQP 7.61 5.12 ± 0.07 1.70 ± 0.47 50 A1:SVGSSLIFLGAYFNRVPDLPYAPCIQ 7.86 5.11 ± 0.05 1.62 ± 0.10 8 \Delta 2:SVGSSLIFLGAYFNRVPDLPYAPCIQ 6.40 5.20 ± 0.05 1.72 ± 0.08 8 \Delta 3:SVGSSLIFLGAYFNRVPDLPYAPCI 6.40 5.04 ± 0.06 1.47 ± 0.17 8 \Delta 4:SVGSSLIFLGAYFNRVPDLPYAP 9.26 5.04 ± 0.06 1.47 ± 0.17 8 \Delta 4:SVGSSLIFLGAYFNRVPDLPYAP 9.26 5.04 ± 0.05b 1.87 ± 0.25 8 \Delta 16:SVGSSLIFLGAYFNRVPDL 6.20 5.22 ± 0.10 1.75 ± 0.25 8 \Delta 16:SVGSSLIFLGAYFN 3.47 5.46 ± 0.05b 1.87 ± 0.22 8 \Delta 16:SVGSSLIFLGAYFN 3.47 5.46 ± 0.05b 1.87 ± 0.22 8 \Delta 16:SVGSSLIF$ | Δ12:WIFLQGVYNQPPPQPFPGD | 9.90 | 5.01 ± 0.06 | 1.32 ± 0.18 | 8 | | |
| $\Delta 20:WIFLQGVYNQP$ 15.1 $4.84 \pm 0.12^{\circ}$ 1.51 ± 0.20 8 $\Delta 24:WIFLQGV$ 7.59 5.12 ± 0.01 1.55 ± 0.13 3 $\Delta 28:WIF$ No current ^c - - 8 ε subunit WT:SVGSSLIFLGAYFNRVPDLPYAPCIQP 7.61 5.12 ± 0.07 1.70 ± 0.47 50 $\Delta 1:SVGSSLIFLGAYFNRVPDLPYAPCIQ 7.86 5.11 \pm 0.05 1.62 \pm 0.10 8 \Delta 2:SVGSSLIFLGAYFNRVPDLPYAPCI 6.40 5.20 \pm 0.05 1.72 \pm 0.08 8 \Delta 3:SVGSSLIFLGAYFNRVPDLPYAPCI 6.40 5.00 \pm 0.05 1.67 \pm 0.11 9 \Delta 4:SVGSSLIFLGAYFNRVPDLPYAPC 8.44 5.08 \pm 0.07 1.67 \pm 0.11 9 \Delta 4:SVGSSLIFLGAYFNRVPDLYAPC 8.44 5.04 \pm 0.06 1.47 \pm 0.17 8 \Delta 4:SVGSSLIFLGAYFNRVPDL 6.20 5.22 \pm 0.10 1.75 \pm 0.25 8 \Delta 13:SVGSSLIFLGAYFNRVPDL 6.20 5.22 \pm 0.10 1.75 \pm 0.22 8 \Delta 16:SVGSSLIFLGAYFN 3.47 5.46 \pm 0.05^{b} 1.87 \pm 0.22 8 \Delta 16:SVGSSLIFLGA 4.22 5.38 \pm 0.06^{b} 1.87 $ | $\Delta 16: WIFLQGVYNQPPPQP$ | 14.2 | 4.85 ± 0.07^{b} | 1.68 ± 0.24 | 8 | | |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | $\Delta 20: WIFLQGVYNQP$ | 15.1 | 4.84 ± 0.12^{6} | 1.51 ± 0.20 | 8 | | |
| $\Delta 28:WIF$ No current ⁶ - - - 8 ε subunit wT:SVGSSLIFLGAYFNRVPDLPYAPCIQP 7.61 5.12 ± 0.07 1.70 ± 0.47 50 $\Delta 1:SVGSSLIFLGAYFNRVPDLPYAPCIQ$ 7.86 5.11 ± 0.05 1.62 ± 0.10 8 $\Delta 2:SVGSSLIFLGAYFNRVPDLPYAPCI$ 6.40 5.20 ± 0.05 1.72 ± 0.08 8 $\Delta 3:SVGSSLIFLGAYFNRVPDLPYAPCI$ 6.40 5.00 ± 0.05 1.72 ± 0.08 8 $\Delta 4:SVGSSLIFLGAYFNRVPDLPYAPC 8.44 5.08 \pm 0.07 1.67 \pm 0.11 9 \Delta 4:SVGSSLIFLGAYFNRVPDLPYAPC 8.44 5.04 \pm 0.06 1.47 \pm 0.17 8 \Delta 8:SVGSSLIFLGAYFNRVPDL 6.20 5.22 \pm 0.10 1.75 \pm 0.25 8 \Delta 13:SVGSSLIFLGAYFN 3.47 5.46 \pm 0.05^{b} 1.87 \pm 0.24 8 \Delta 16:SVGSSLIFLGA 4.22 5.38 \pm 0.06^{b} 1.87 \pm 0.22 8 \Delta 16:SVGSSLIFLGA 4.22 5.38 \pm 0.06^{b} 1.87 \pm 0.22 8 \Delta 16:SVGSSLIFL 1.21 5.92 \pm 0.09^{b} 1.87 \pm 0.37 4 \Delta 20:SVGSSLIFL No currentc -$ | Δ24:WIFLQGV | 7.59 | 5.12 ± 0.01 | 1.55 ± 0.13 | 3 | | |
| | $\Delta 28: \dots WIF$ | No current ^e | — | — | 8 | | |
| WT:SVGSSLIFLGAYFNRVPDLPYAPCIQP7.61 5.12 ± 0.07 1.70 ± 0.47 50 $\Delta 1:$ SVGSSLIFLGAYFNRVPDLPYAPCIQ7.86 5.11 ± 0.05 1.62 ± 0.10 8 $\Delta 2:$ SVGSSLIFLGAYFNRVPDLPYAPCI 6.40 5.20 ± 0.05 1.72 ± 0.08 8 $\Delta 3:$ SVGSSLIFLGAYFNRVPDLPYAPC 8.44 5.08 ± 0.07 1.67 ± 0.11 9 $\Delta 4:$ SVGSSLIFLGAYFNRVPDLPYAPC 8.44 5.04 ± 0.06 1.47 ± 0.17 8 $\Delta 8:$ SVGSSLIFLGAYFNRVPDL 6.20 5.22 ± 0.10 1.75 ± 0.25 8 $\Delta 13:$ SVGSSLIFLGAYFN 3.47 5.46 ± 0.05^{b} 1.87 ± 0.24 8 $\Delta 16:$ SVGSSLIFLGA 4.22 5.38 ± 0.06^{b} 1.87 ± 0.22 8 $\Delta 18:$ SVGSSLIFLGA 1.21 5.92 ± 0.09^{b} 1.87 ± 0.37 4 $\Delta 20:$ SVGSSLIFL 1.21 5.92 ± 0.09^{b} 1.87 ± 0.37 4 $\Delta 24:$ SVGNo current ^C 8 | ε subunit | | | | | | |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | WT:SVGSSLIFLGAYFNRVPDLPYAPCIQP | 7.61 | 5.12 ± 0.07 | 1.70 ± 0.47 | 50 | | |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | $\Delta 1$:SVGSSLIFLGAYFNRVPDLPYAPCIQ | 7.86 | 5.11 ± 0.05 | 1.62 ± 0.10 | 8 | | |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | $\Delta 2$:SVGSSLIFLGAYFNRVPDLPYAPCI | 6.40 | 5.20 ± 0.05 | 1.72 ± 0.08 | 8 | | |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | $\Delta 3: SVGSSLIFLGAYFNRVPDLPYAPC$ | 8.44 | 5.08 ± 0.07 | 1.67 ± 0.11 | 9 | | |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | $\Delta 4$:SVGSSLIFLGAYFNRVPDLPYAP | 9.26 | 5.04 ± 0.06 | 1.47 ± 0.17 | 8 | | |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | Δ8:SVGSSLIFLGAYFNRVPDL | 6.20 | 5.22 ± 0.10 | 1.75 ± 0.25 | 8 | | |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | Δ13:SVGSSLIFLGAYFN | 3.47 | 5.46 ± 0.05^{b} | 1.87 ± 0.24 | 8 | | |
| $\Delta 18: \dots$ SVGSSLIFL 1.89 5.74 ± 0.13^{b} 1.99 ± 0.16 9 $\Delta 20: \dots$ SVGSSLI 1.21 5.92 ± 0.09^{b} 1.87 ± 0.37 4 $\Delta 24: \dots$ SVG No current ^c - - 8 | Δ16:SVGSSLIFLGA | 4.22 | 5.38 ± 0.06^{b} | 1.87 ± 0.22 | 8 | | |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | $\Delta 18:SVGSSLIFL$ | 1.89 | 5.74 ± 0.13^{b} | 1.99 ± 0.16 | 9 | | |
| $\Delta 24: \dots SVG$ No current ^c 8 | $\Delta 20:SVGSSLI$ | 1.21 | 5.92 ± 0.09^{b} | 1.87 ± 0.37 | 4 | | |
| | Δ24:SVG | No current ^c | _ | _ | 8 | | |

^a Measurements performed 1 to 4 days after cRNA injection (V_{hold} ranging from -20 to -80 mV). Error values are represented as standard deviation.

 $^{b} p < 0.001$ relative to WT via one-way ANOVA followed by Dunnet's post hoc test.

^c No significant current observed up to 4 days after cRNA injection.

function. In the δ subunit, the δ S240A mutant on M1 did not functionally express. In contrast, the ϵ S235A mutation in M1 of the ϵ subunit enhances ϵ F446W-induced potentiation suggesting that an interaction between F446W and ϵ S235 is detrimental to ϵ F446W-induced potentiation. These data illustrate how even analogous changes in the structure of M4 from different subunits can lead to different effects on channel function.

M4 mutations in different subunits are additive

We previously observed with that the subtle functional effects of individual alanine mutations along $\alpha M4$ are additive and thus can cumulatively lead to much larger changes in channel function. This implies that a reorientation of M4 could modulate many interactions at the M4–M1/M3

interface with functional effects of the individual alterations in structure adding up to a more substantial effect. Here, we tested whether mutations on different M4 α -helices are additive. Specifically, we focused on three positions where individual mutations in α M4 (α F426A, α V425A, and α C418W) lead to relatively large changes in function. We produced the equivalent mutations in the remaining β , δ , and ε subunits and then assessed the effect on function when all mutated subunits were expressed at the same time.

A phenylalanine at equivalent positions near the C terminus of M4 in all four subunits, α Phe426, β Phe464, δ Phe468, and ϵ Phe454, projects toward α M1 and α M3. The alanine mutation of each residue individually led to a 3.8-fold gain-, a 1.1-fold loss-, a 1.3-fold gain-, and a 2.0-fold gain-of-function, respectively. The simultaneous quadruple mutant, α F426A + β F464A + δ F468A + ϵ F454A, led to an 11.4-fold gain of



Figure 5. Aromatic residues along the M4–M1/M3 interface in each subunit. Top-down (*top*) and side (*bottom*) views of each subunit's TMD with aromatic residues at the M4–M1/M3 interface shown as *yellow sticks*. TMD, transmembrane domain.

function (Table 5), which is close to the 8.6-fold gain of function predicted if the functional effects of the mutations are independent and thus additive. Similarly, the adjacent α V426A, β I464A, δ I468A, and ϵ I454A mutants individually led to a 1.8-fold, a 2.1-fold, a 1.6-fold, and a 1.7-fold gain of function, respectively, with the quadruple α V426A + β I464A + δ I468A + ϵ I454A mutant leading to a 12.1-fold gain of function, again a value close to the 10.2-fold gain of function expected for independent additive mutations. Finally, the α C418W, β T456W, δ M460W, and ϵ F446W mutants noted previously led to a 16-fold gain-, a 1.7-fold gain-, a 1.6-fold loss-, and a 1.8-fold gain-of-function, respectively. The quadruple α C418W + β T456W + δ M460W + ϵ F446W mutant led to a 30.0-fold gain of function, virtually the same as that predicted (30.7-fold) for independent additive mutations.

M4 mutations have different effects on nAChR function in different membrane environments

Recent studies have shown that mutations in the M4 α helix of the homopentameric 5-HT3_A receptor have different effects on function when the receptor is expressed in HEK293T cells *versus Xenopus* oocytes, with the different phenotypes attributed to the different lipid compositions of the plasma membranes (39). To determine if the functional effects of M4 mutations in the muscle nAChR are also

dependent on their cellular context, we characterized six αM4 mutants in HEK293T cells using a membrane potential-sensitive fluorescent dye (Fig. S2). Although the measured EC₅₀ values obtained using the fluorescent dye differ from those measured using TEVC electrophysiology in oocytes, we observed that two single $\alpha M4$ Ala mutants, αF414A and αF426A, gave rise to similar fold changes in EC₅₀ values relative to the WT nAChR in both heterologous expression systems (Table 6). In contrast, both aD407A and aR429A did not give rise to an agonist-induced response. $[^{125}I]$ - α -bungarotoxin (α -BTX; PerkinElmer) binding showed that while aR429A did not express, aD407A expressed well above background levels (Table 6). The α D407A mutant receptors that do reach the cell surface are thus unable to produce an agonist-induced response. Even though aD407A leads to a slight gain of function when expressed in Xenopus oocytes, the same aD407A mutation renders the nAChR inactive in HEK293T cells.

We also examined the functional effects of two triple M4 mutants. The first triple mutant, α L411A + α T422A + α R429A, led to a similar loss in function in both cell types (eightfold and sixfold loss of function in HEK293T cells *versus* oocytes, respectively). In contrast, the second triple mutant, α D407A + α F414A + α F426A, led to a complete loss of a response in HEK293T cells despite expressing at levels consistent with the α D407A mutant. Overall, the data show

Table 3

Effects of mutating aromatic residues at the M4–M1/M3 interface on nAChR function

| MutationTMD α-helixEC ₅₀ (μM)pEC ₅₀ (M)Hill slopenWT7.61 5.12 ± 0.07 1.70 ± 0.47 50α subunitaf227AM16.51 5.20 ± 0.09 1.43 ± 0.16 8af227AM12.63 $5.58 \pm 0.05^{\circ}$ 1.63 ± 0.20 9a1233AM12.63 $5.58 \pm 0.05^{\circ}$ 1.63 ± 0.20 9a1234AM1No current ⁶ 8a1230AM3 4.25 $5.38 \pm 0.01^{\circ}$ 1.78 ± 0.58 8a1230AM3 4.25 $5.38 \pm 0.01^{\circ}$ 1.56 ± 0.29 8a1234AM3 4.80 $5.32 \pm 0.07^{\circ}$ 1.33 ± 0.21 9a1244AM4 4.47 $5.36 \pm 0.09^{\circ}$ 1.76 ± 0.34 10a12426AM4 2.02 $5.71 \pm 0.14^{\circ}$ 1.80 ± 0.76 11β subunit9β245AM1 7.44 5.13 ± 0.10 1.56 ± 0.16 7β245AM4 4.36 $5.35 \pm 0.14^{\circ}$ 2.23 ± 0.77 9β245AM4 4.36 $5.35 \pm 0.10^{\circ}$ 1.66 ± 0.35 9β245AM4 4.36 $5.35 \pm 0.10^{\circ}$ 1.66 ± 0.35 9β245AM4 4.36 $5.35 \pm 0.10^{\circ}$ 1.65 ± 0.16 7β245AM4 0.55 5.08 ± 0.11 1.38 ± 0.19 10δ subunit g g g 1.66 ± 0.35 99 | Dose response ^a | | | | | | | |
|---|----------------------------|-------------|-------------------------|-----------------------|-----------------|----|--|--|
| WT7.61 5.12 ± 0.07 1.70 ± 0.47 50a subunitaf227AM16.51 5.20 ± 0.09 1.43 ± 0.16 8af223AM12.63 5.58 ± 0.05^{5} 1.63 ± 0.20 9aY23AAM1No current ^c aY27AM311.2 4.96 ± 0.08^{5} 1.78 ± 0.58 8aF280AM3 4.25 5.38 ± 0.11^{5} 1.56 ± 0.29 8aF284AM3 4.80 5.32 ± 0.07^{5} 1.33 ± 0.21 9aF414AM4 4.47 5.36 ± 0.09^{5} 1.76 ± 0.34 10aF426AM42.02 5.71 ± 0.14^{5} 1.80 ± 0.76 11βE244AM1 4.46 5.35 ± 0.14^{5} 2.23 ± 0.77 9gY245AM1 7.44 5.13 ± 0.10 1.56 ± 0.16 7gY28AM3 5.43 5.27 ± 0.10^{5} 1.63 ± 0.48 8gF291AM3 10.5 4.98 ± 0.09^{5} 1.63 ± 0.48 8gF448AM4 4.36 5.38 ± 0.15^{5} 1.63 ± 0.48 8gF464AM4 8.55 5.08 ± 0.11 1.38 ± 0.19 10δ subunit 6.18 5.21 ± 0.08 1.62 ± 0.16 9 δ δ δ δ δ δ δ β δ δ δ δ δ δ β δ δ δ δ δ δ β δ δ δ δ δ δ | Mutation | TMD α-helix | EC ₅₀ (µM) | pEC ₅₀ (M) | Hill slope | n | | |
| a subunita constraint of the second se | WT | | 7.61 | 5.12 ± 0.07 | 1.70 ± 0.47 | 50 | | |
| $af 227A$ M16.515.20 ± 0.091.43 ± 0.168 $af 233A$ M12.635.58 ± 0.05b1.63 ± 0.209 $aY234A$ M1No current ⁶ ——8 $aY277A$ M311.24.96 ± 0.08b1.78 ± 0.5888 $af 280A$ M34.255.38 ± 0.1b1.55 ± 0.298 $af 284A$ M34.805.32 ± 0.07b1.33 ± 0.219 $af 414A$ M44.475.36 ± 0.09b1.76 ± 0.3410 $af 426A$ M42.025.71 ± 0.14b1.80 ± 0.7611 β isbunit————9 $\beta 2245A$ M17.445.13 ± 0.101.56 ± 0.167 $\beta Y285A$ M17.445.13 ± 0.101.56 ± 0.167 $\beta Y285A$ M35.435.27 ± 0.10b1.77 ± 0.308 $\beta F291A$ M310.54.98 ± 0.09b1.66 ± 0.359 $\beta F448A$ M44.365.38 ± 0.15b1.63 ± 0.488 $\beta F445A$ M410.54.98 ± 0.07b1.63 ± 0.488 $\beta F445A$ M43.675.44 ± 0.12b99 $\delta Y248A$ M13.675.44 ± 0.12b1.57 ± 0.229 $\delta F294A$ M33.865.41 ± 0.07b1.72 ± 0.138 $\delta F294A$ M33.865.21 ± 0.0299 $\delta F294A$ M36.185.21 ± 0.101.76 ± 0.1110 $\delta F294A$ M36.125.09 ± | α subunit | | | | | | | |
| af 233AM12.63 $5.58 \pm 0.05^{\circ}$ 1.63 ± 0.20 9aY234AM1No current ^c 8aY277AM311.2 $4.96 \pm 0.08^{\circ}$ 1.78 ± 0.58 8af 280AM3 4.25 $5.38 \pm 0.11^{\circ}$ 1.56 ± 0.29 8af 284AM3 4.80 $5.32 \pm 0.07^{\circ}$ 1.33 ± 0.21 9af 44AM4 2.02 $5.71 \pm 0.14^{\circ}$ 1.80 ± 0.76 11 β submit9 β 2245AM1 4.46 $5.35 \pm 0.14^{\circ}$ 2.23 ± 0.77 9 β Y245AM1 7.44 5.13 ± 0.10 1.56 ± 0.16 7 β Y245AM1 7.44 $5.13 \pm 0.10^{\circ}$ 1.77 ± 0.30 8 β F291AM3 10.5 $4.98 \pm 0.09^{\circ}$ 1.66 ± 0.35 9 β F448AM4 0.55 $5.08 \pm 0.15^{\circ}$ 1.63 ± 0.48 8 β F452AM4 10.5 4.98 ± 0.07 1.69 ± 0.11 8 δ F448AM4 8.55 $5.08 \pm 0.11^{\circ}$ 1.65 ± 0.12 9 δ Submit δ F448AM1 3.66 $5.21 \pm 0.06^{\circ}$ 1.67 ± 0.12 9 δ F247AM1 8.12 5.09 ± 0.04 1.67 ± 0.11 10 δ F248AM3 3.86 $5.11 \pm 0.07^{\circ}$ 1.57 ± 0.12 9 δ F248AM4 8.82 $5.05 \pm 0.10^{\circ}$ 1.51 ± 0.13 9 δ F248AM4< | αF227A | M1 | 6.51 | 5.20 ± 0.09 | 1.43 ± 0.16 | 8 | | |
| aY234AM1No current ⁶ 8aY277AM311.24.96 \pm 0.08 ^b 1.78 \pm 0.5888aF280AM34.255.38 \pm 0.11 ^b 1.56 \pm 0.298aF284AM34.805.32 \pm 0.07 ^b 1.33 \pm 0.219aF414AM44.475.36 \pm 0.09 ^b 1.76 \pm 0.3410aF426AM42.025.71 \pm 0.14 ^b 1.80 \pm 0.7611 β subunit9BF244AM14.465.35 \pm 0.14 ^b 2.23 \pm 0.779 β Y245AM17.445.13 \pm 0.101.56 \pm 0.167 β Y28AM35.435.27 \pm 0.10 ^b 1.77 \pm 0.308 β F291AM310.54.98 \pm 0.09 ^b 1.66 \pm 0.359 β F448AM44.365.38 \pm 0.15 ^b 1.63 \pm 0.488 β F452AM410.54.98 \pm 0.071.69 \pm 0.118Subunit δ F247AM111.24.95 \pm 0.10 ^b 1.45 \pm 0.129 δ F247AM13.675.44 \pm 0.12 ^b 1.57 \pm 0.229 δ F247AM13.675.44 \pm 0.12 ^b 1.57 \pm 0.229 δ F247AM13.675.41 \pm 0.07 ^b 1.72 \pm 0.138 δ F248AM45.835.25 \pm 0.101.67 \pm 0.129 δ F247AM18.125.09 \pm 0.041.67 \pm 0.1110 <td>αF233A</td> <td>M1</td> <td>2.63</td> <td>5.58 ± 0.05^{b}</td> <td>1.63 ± 0.20</td> <td>9</td> | αF233A | M1 | 2.63 | 5.58 ± 0.05^{b} | 1.63 ± 0.20 | 9 | | |
| a Y277AM311.2 4.96 ± 0.08^b 1.78 ± 0.58 8a F280AM3 4.25 5.38 ± 0.11^b 1.56 ± 0.29 8a F284AM3 4.80 5.32 ± 0.07^b 1.33 ± 0.21 9a F414AM4 4.47 5.36 ± 0.09^b 1.76 ± 0.34 10a F426AM4 2.02 5.71 ± 0.14^b 1.80 ± 0.76 11 β subunit γ γ 9 γ γ 9 β Y245AM1 7.44 5.13 ± 0.10 1.56 ± 0.16 7 β Y288AM3 5.43 5.27 ± 0.10^b 1.77 ± 0.30 8 β F244AM4 4.36 5.38 ± 0.15^b 1.63 ± 0.48 8 β F448AM4 4.36 5.38 ± 0.07 1.63 ± 0.48 8 β F448AM4 0.55 5.08 ± 0.07 1.69 ± 0.11 8 β F448AM4 3.67 5.08 ± 0.17 1.65 ± 0.12 9 δ F247AM1 11.2 4.95 ± 0.10^b 1.45 ± 0.12 9 δ Suburit δ F247AM1 11.2 4.95 ± 0.10^b 1.45 ± 0.12 9 δ F248AM1 3.67 5.44 ± 0.12^b 1.62 ± 0.16 9 δ F247AM1 1.27 4.90 ± 0.06^b 1.51 ± 0.13 9 δ F248AM3 6.18 5.21 ± 0.08 1.62 ± 0.16 9 δ F248A | αY234A | M1 | No current ^c | — | _ | 8 | | |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | αY277A | M3 | 11.2 | 4.96 ± 0.08^{b} | 1.78 ± 0.58 | 8 | | |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | αF280A | M3 | 4.25 | 5.38 ± 0.11^{b} | 1.56 ± 0.29 | 8 | | |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | αF284A | M3 | 4.80 | 5.32 ± 0.07^{b} | 1.33 ± 0.21 | 9 | | |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | αF414A | M4 | 4.47 | 5.36 ± 0.09^{b} | 1.76 ± 0.34 | 10 | | |
| $ \begin{array}{c c c c c c c c c c c c c c c c c c c $ | αF426A | M4 | 2.02 | 5.71 ± 0.14^{b} | 1.80 ± 0.76 | 11 | | |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | β subunit | | | | | | | |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | βF244A | M1 | 4.46 | 5.35 ± 0.14^{b} | 2.23 ± 0.77 | 9 | | |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | βY245A | M1 | 7.44 | 5.13 ± 0.10 | 1.56 ± 0.16 | 7 | | |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | βY288A | M3 | 5.43 | 5.27 ± 0.10^{b} | 1.77 ± 0.30 | 8 | | |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | βF291A | M3 | 10.5 | 4.98 ± 0.09^{b} | 1.66 ± 0.35 | 9 | | |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | βF448A | M4 | 4.36 | 5.38 ± 0.15^{b} | 1.63 ± 0.48 | 8 | | |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | βF452A | M4 | 10.5 | 4.98 ± 0.07 | 1.69 ± 0.11 | 8 | | |
| $ \begin{split} \delta \begin{tabular}{ c c c c c } \hline \delta \begin{tabular}{ c c c c } \hline \delta \begin{tabular}{ c c } $ | βF464A | M4 | 8.55 | 5.08 ± 0.11 | 1.38 ± 0.19 | 10 | | |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | δ subunit | | | | | | | |
| $ \begin{array}{cccccccccccccccccccccccccccccccccccc$ | δF247A | M1 | 11.2 | 4.95 ± 0.10^{b} | 1.45 ± 0.12 | 9 | | |
| | δY248A | M1 | 3.67 | 5.44 ± 0.12^{b} | 1.57 ± 0.22 | 9 | | |
| | δF291A | M3 | 6.18 | 5.21 ± 0.08 | 1.62 ± 0.16 | 9 | | |
| | δF294A | M3 | 3.86 | 5.41 ± 0.07^{b} | 1.72 ± 0.13 | 8 | | |
| $\begin{array}{c c c c c c c c c c c c c c c c c c c $ | δF468A | M4 | 5.83 | 5.25 ± 0.10 | 1.60 ± 0.27 | 7 | | |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | ε subunit | | | | | | | |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | εY242A | M1 | 8.12 | 5.09 ± 0.04 | 1.67 ± 0.11 | 10 | | |
| ϵ F287AM312.7 4.90 ± 0.06^{b} 1.51 ± 0.13 9 ϵ F290AM3 6.14 5.21 ± 0.12 2.06 ± 0.36 7 ϵ F439AM4 8.59 5.07 ± 0.07 1.81 ± 0.08 8 ϵ F446AM4 8.89 5.06 ± 0.07 1.51 ± 0.18 9 ϵ F454AM4 3.90 5.42 ± 0.10^{b} 1.80 ± 0.25 8 | εF243A | M1 | 8.02 | 5.10 ± 0.10 | 1.78 ± 0.19 | 9 | | |
| $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | εF287A | M3 | 12.7 | 4.90 ± 0.06^{b} | 1.51 ± 0.13 | 9 | | |
| ϵ F439AM48.59 5.07 ± 0.07 1.81 ± 0.08 8 ϵ F446AM48.89 5.06 ± 0.07 1.51 ± 0.18 9 ϵ F454AM4 3.90 5.42 ± 0.10^{b} 1.80 ± 0.25 8 | εF290A | M3 | 6.14 | 5.21 ± 0.12 | 2.06 ± 0.36 | 7 | | |
| ϵ F446AM48.89 5.06 ± 0.07 1.51 ± 0.18 9 ϵ F454AM4 3.90 5.42 ± 0.10^{b} 1.80 ± 0.25 8 | εF439A | M4 | 8.59 | 5.07 ± 0.07 | 1.81 ± 0.08 | 8 | | |
| ϵ F454A M4 3.90 5.42 ± 0.10 ^b 1.80 ± 0.25 8 | εF446A | M4 | 8.89 | 5.06 ± 0.07 | 1.51 ± 0.18 | 9 | | |
| | εF454A | M4 | 3.90 | 5.42 ± 0.10^{b} | 1.80 ± 0.25 | 8 | | |

^a Measurements performed 1 to 4 days after cRNA injection (V_{hold} ranging from -20 to -80 mV). Error values are represented as standard deviation.

^b p < 0.001 relative to WT via one-way ANOVA followed by Dunnet's post hoc test.

^c No significant current observed up to 4 days after cRNA injection.

that the functional effects of select mutations within α M4 in the human muscle nAChR are different in HEK293T cells and oocytes.

Discussion

The goal of this work was to probe how the structure of the M4 α -helix from each of the four distinct nAChR subunits influences channel function as a foundation for understanding the role played by each as a lipid sensor. In particular, we

hoped to identify putative interactions involving residues on each M4 that are essential to channel function and that could be modulated by lipids to stabilize the nonactivatable uncoupled state that forms in phosphatidylcholine membranes lacking cholesterol and anionic lipids (5). To identify interactions that are essential to channel function, we generated alanine mutations of every M4 residue in each subunit. Surprisingly, all the generated mutants expressed robustly in frog oocytes except for one, ε M430A, which extends toward a structure, ε MX, that has been implicated in assembly/cell

Table 4

Interactions between the α C418W mutant and its equivalents and adjacent residues from M1

| | Dose response ^a | | | | | | | Fold change | |
|------------|----------------------------|-----------------------|-----------------|--------|-----------------------|-----------------------|-----------------|------------------------------|---|
| | WT | | | αC418W | | | | $\left[EC_{50}(WT) \right]$ | |
| Background | EC ₅₀ (µM) | pEC ₅₀ (M) | Hill slope | n | EC ₅₀ (μM) | pEC ₅₀ (M) | Hill slope | n | $\overline{\text{EC}_{50}(\text{mut})}$ |
| WT | 7.61 | 5.12 ± 0.07 | 1.70 ± 0.47 | 50 | 0.47 | 6.33 ± 0.13^{b} | 1.54 ± 0.23 | 50 | 16.2 |
| αS226A | 12.3 | 4.92 ± 0.11^{b} | 1.70 ± 0.47 | 8 | 3.66 | 5.45 ± 0.11^{b} | 1.26 ± 0.12 | 8 | 3.4 |
| | WT | | | | βT456W | | | | |
| WT | 7.61 | 5.12 ± 0.07 | 1.70 ± 0.47 | 50 | 4.50 | 5.36 ± 0.10^{b} | 1.73 ± 0.17 | 10 | 1.7 |
| βT237A | 6.28 | 5.22 ± 0.16 | 1.77 ± 0.10 | 8 | 4.26 | 5.38 ± 0.07^{b} | 1.59 ± 0.11 | 8 | 1.5 |
| • | WT | | | | δM460W | | | | |
| WT | 7.61 | 5.12 ± 0.07 | 1.70 ± 0.47 | 50 | 12.1 | 4.93 ± 0.12^{b} | 1.41 ± 0.16 | 9 | 0.6 |
| δS240A | No current ^c | _ | _ | 8 | 5.89 | 5.23 ± 0.07 | 1.83 ± 0.17 | 4 | _ |
| | WT | | | | εF446W | | | | |
| WT | 7.61 | 5.12 ± 0.07 | 1.70 ± 0.47 | 50 | 4.26 | 5.39 ± 0.14^{b} | 1.75 ± 0.13 | 9 | 1.8 |
| εS235A | 1.39 | 5.86 ± 0.06^{b} | 1.78 ± 0.43 | 4 | 0.38 | 6.43 ± 0.11^{b} | 1.74 ± 0.47 | 8 | 3.7 |

^a Measurements performed 1 to 4 days after cRNA injection (V_{hold} ranging from -20 to -80 mV). Error values are represented as standard deviation.

^b p < 0.001 relative to WT via one-way ANOVA followed by Dunnet's post hoc test.

^c No significant current observed up to 4 days after cRNA injection.

| Table 5 | | | | |
|----------------------|---------------------|--------------------|-------------------|-------------|
| Mutations to aligned | residues in each M4 | a-helix have indep | pendent effects o | on function |

| | Dose response ^a | | | | | |
|--|----------------------------|----------------------------|-----------------|----|----------|------------------------|
| Mutation(s) | EC ₅₀ (µM) | pEC ₅₀ (M) | Hill slope | n | Fold | change |
| WT | 7.61 | 5.12 ± 0.07^{b} | 1.70 ± 0.47 | 50 | Observed | Predicted ^c |
| αF426A | 2.02 | 5.71 ± 0.14^{b} | 1.80 ± 0.76 | 11 | 3.76 | _ |
| βF464A | 8.55 | 5.08 ± 0.11 | 1.38 ± 0.19 | 10 | 0.89 | _ |
| δF468A | 5.83 | 5.25 ± 0.10 | 1.60 ± 0.27 | 7 | 1.31 | _ |
| εF454A | 3.90 | 5.42 ± 0.10^{b} | 1.80 ± 0.25 | 8 | 1.95 | _ |
| α F426A + β F464A + δ F468A + ϵ F454A | 0.67 | 6.17 ± 0.17^{b} | 2.04 ± 0.15 | 8 | 11.4 | 8.54 |
| αV425A | 4.30 | 5.37 ± 0.05^{b} | 1.89 ± 0.28 | 10 | 1.77 | _ |
| βI463A | 3.67 | $5.44 \pm 0.16^{\text{b}}$ | 1.78 ± 0.11 | 8 | 2.07 | _ |
| δΙ467Α | 4.63 | 5.34 ± 0.07^{b} | 1.91 ± 0.79 | 7 | 1.65 | _ |
| εI453A | 4.50 | 5.35 ± 0.06^{b} | 1.83 ± 0.27 | 8 | 1.69 | _ |
| αV425A + βI463A + δI467A + εI453A | 0.63 | 6.20 ± 0.17^{b} | 2.11 ± 0.28 | 7 | 12.1 | 10.2 |
| αC418W | 0.47 | 6.33 ± 0.13^{b} | 1.54 ± 0.23 | 50 | 16.2 | _ |
| βT456W | 4.50 | 5.36 ± 0.10^{b} | 1.73 ± 0.17 | 10 | 1.69 | _ |
| δM460W | 12.2 | 4.93 ± 0.12^{b} | 1.41 ± 0.16 | 9 | 0.63 | _ |
| εF446W | 4.26 | 5.39 ± 0.14^{b} | 1.75 ± 0.13 | 9 | 1.79 | _ |
| $\alpha C418W + \beta T456W + \delta M460W + \epsilon F446W$ | 0.25 | 6.60 ± 0.08^{b} | 1.90 ± 0.58 | 9 | 30.0 | 30.7 |

^a Measurements performed 1 to 4 days after cRNA injection (V_{hold} ranging from -20 to -80 mV). Error values are represented as standard deviation.

 $^{b} p < 0.001$ relative to WT via one-way ANOVA followed by Dunnet's post hoc test.

^c Predicted fold change if individual mutations affect function independently.

surface trafficking (28). Of those that expressed, 54 of 155 mutations led to statistically significant changes in the measured EC_{50} values and thus in channel function. Of these, only eight, however, led to shifts in EC_{50} values greater than approximately twofold, with α T422A and α R429A leading to 4.1-fold and 5.3-fold loss-of-function, respectively, and α F426A and β V444A leading to 3.8-fold and 3.4-fold gains-infunction, respectively. Although the detected changes in EC_{50} values confirm that interactions involving residues on M4 from each subunit influence channel function, there are likely no essential individual interactions that could be modulated by lipids to form the uncoupled state.

We also examined whether the post-M4 sequence in each subunit, which extends above the lipid bilayer, forms interactions with the ECD that are important to channel gating. We created a total of 51 Ala mutations in the post-M4 segments of the α , β , δ , and ε subunits, but all 51 of these mutants led to functional nAChRs with none altering the measured EC₅₀ values by more than approximately twofold. Furthermore, deleting various regions or the entire post-M4 segment from any subunit ($\alpha\Delta5$, $\beta\Delta10$, $\delta\Delta24$, and $\varepsilon\Delta16$) had minimal detrimental effects on the measured EC₅₀ values. In fact, some

deletions, such as $\varepsilon \Delta 24$, led to relatively large (6.3-fold) gains of function. These results suggest that there are no functionally essential interactions involving residues in post-M4 from any subunit.

The lack of essential interactions involving residues on M4 or post-M4 contrasts what has been observed in other pLGICs (23, 30, 32, 33, 40) and leads to a question as to how some lipid environments stabilize a nonactivatable uncoupled state. One possibility is that lipid-dependent uncoupling results from the cumulative effects of many changes in interactions involving residues on M4 that individually have only subtle impacts on channel function. This possibility is supported by two observations. First, the functional effects of multiple alanine substitutions on a single M4 *a*-helix are additive with simultaneous mutations leading to more pronounced effects on channel function, in some cases actually preventing functional expression altogether (26). Second, the functional effects of mutations of residues on the M4 α-helices from different subunits are additive with multiple simultaneous mutations leading to large cumulative effects. For example, simultaneous mutations of residues in each subunit equivalent to aV425A, α F426A, or α C418W led to 12.1-, 11.4-, and 30.4-fold changes

7.68

3

3

9

 1.87 ± 0.40

| iffects of M4 mutations on nAChR function and expression in HER2931 cells | | | | | | | | |
|---|----------------------------|-----------------------|-----------------|---|-------------|---|--|--|
| | Dose response ^a | | | | | | | |
| Mutation(s) | EC ₅₀ (μM) | pEC ₅₀ (M) | Hill slope | n | Fold change | | | |
| WT | 0.30 | 6.54 ± 0.13 | 1.58 ± 0.32 | 9 | | _ | | |
| αD407A | _ | d | _ | 3 | _ | | | |
| αF414A | 0.33 | 6.48 ± 0.06 | 1.41 ± 0.22 | 4 | 1.10 | | | |
| αF426A | 0.09 | 7.04 ± 0.09^{e} | 1.12 ± 0.22 | 3 | 0.31 | | | |
| αR429A | _ | d | _ | 3 | _ | | | |

 5.64 ± 0.12

^a Measurements performed 2 days post-transfection. Error values are represented as standard deviation.

2.31

^b Measurements performed 2 days post-transfection in triplicate. Error values are represented as standard deviation.

p < 0.001 relative to untransfected cells *via* one-way ANOVA followed by Dunnet's post hoc test.

^d No agonist-induced response was observed.

αF426A + F414A + D407A

αR429A + T422A + L411A

 $^{e} p < 0.001$ relative to WT via one-way ANOVA followed by Dunnet's post hoc test.

Untransfected

Table 6

 $\frac{ [^{125}I] - \alpha - BTX^{b} }{ CPM_{mutant}/CPM_{WT} } \frac{ 1.00 \pm 0.07^{c} }{ 0.23 \pm 0.01^{c,e} } \frac{ - }{ - } \\ 0.08 \pm 0.04^{e} }$

 $0.24 \pm 0.08^{c,c}$

 $0.08 \pm 0.03^{\circ}$

in the recorded EC_{50} values, each close to the 10.2-, 8.6-, and 30.6-fold change in function predicted if the effect of each mutation is independent. Further work will be required to understand how cumulative changes to many subtle interactions involving M4 ultimately influence channel function.

On the other hand, it is intriguing to note that of the 173 alanine mutations characterized in this report, two led to nAChRs that did not functionally express in oocytes. One of the mutants, EM430A (EM4), likely impacts on nAChR assembly/cell surface trafficking. On the other hand, both εM430A and the other nonfunctional expressing mutant, α Y234A (α M1), are located near the cytoplasmic surface of the bilayer close to newly identified phospholipid-binding sites on the Torpedo nAChR and cholesterol-binding sites on the $\alpha 4\beta 2$ and α3β4 nAChRs (14, 16, 17, 41, 42). In fact, αY234 is thought to form part of a phospholipid-binding motif. The lack of functional expression of both these mutants may suggest that impaired lipid binding influences nAChR folding. Such lipidbinding sites could also play a role in lipid sensing. Further studies are currently aimed toward defining the roles of these lipid-binding sites in nAChR function.

Our mutational studies reveal additional features that impact on our understanding of potential mechanisms of lipid sensing via M4. First, our data reveal a common theme that a mutation in M4 from one subunit can have a different effect on function than the analogous mutation in a different subunit. For example, alanine substitutions of α R429, α F426, and αT422A lead to a 5.3-fold loss-, a 3.8-fold gain-, and a 4.1-fold loss of function, respectively. In contrast, alanine substitutions at equivalent sites in β M4 (β T460, β F464, and β A467), δ M4 (δ T464, δ F468, and δ G471), and ϵ M4 (ϵ S450, ϵ F454, and ε A457) have virtually no effect. Even more striking, while the CMS-causing mutation on α M4, α C418W, potentiates channel function 15- to 25-fold primarily through a stabilizing interaction with an adjacent serine residue, α Ser226, on α M1, the analogous tryptophan substitutions in other subunits have little effect on function despite the presence of a homologous serine residue or threonine residue at the same position on M1 in each of the β (β Thr237), δ (δ erS240), and ϵ (ϵ Ser235) subunits. The lack of conservation of function despite a conserved structural motif suggests that the TMD α -helices from each subunit undergo different motions upon channel activation, thus leading to different poses of the M4 α-helix from different subunits relative to their adjacent M1 and M3 α-helices. In agreement, recent cryo-EM structures of the Torpedo nAChR solved in the presence and absence of agonist reveal subunitspecific tertiary deformations in each TMD (16, 17). These findings suggest that the same lipid-induced change in M4 structure in one subunit could have a strikingly different effect on channel function in another subunit.

Second, we found that alanine substitutions of bulky aromatic residues at the M4–M1/M3 interface typically led to subtle and more variable effects on nAChR function (11 of 27 significantly potentiates function) than in some pLGICs. For example, the glycine receptor and the prokaryotic homolog, GLIC, exhibit a complex network of interacting aromatic residues at this interface that is essential to folding and function. In these pLGICs, alanine substitutions of M4-M1/ M3 interfacial aromatic residues invariably lead to losses of function, with multiple substitutions typically leading to a complete loss of functional expression (23, 30). Other pLGICs, such as the prokaryotic pLGIC ELIC, however, have relatively few aromatic residues. In the latter, aromatic to alanine substitutions invariably lead to gains in function suggesting that the bulky aromatic side chains sterically block the formation of M4–M1/M3 interactions that are optimal for channel function (31). Furthermore, the introduction of aromatic residues at the M4-M1/M3 interface in ELIC to mimic the complex aromatic network observed in GLIC not only enhanced ELIC function but renders ELIC less functionally sensitive to its membrane environment (34). While the trends observed with GLIC and ELIC are not adhered to strictly in all pLGICs (23, 30, 32, 33, 40), they have led to the suggestion that a more malleable M4– M1/M3 interface because of a lack of may lead to a more lipidsensitive pLGIC. Our data show that as in ELIC, aromatic-toalanine substitutions are well tolerated in the nAChR, consistent with a more malleable M4-M1/M3 interface that may contribute to a higher sensitivity to its surrounding lipid environment.

Finally, we characterized the effects of select α M4 mutations on nAChR function and expression in HEK293T cells to determine if these mutations have different effects when in membranes that differ in their lipid composition. Previous studies have shown that the effects of M4 mutations in the 5-HT_{3A}R are different when expressed in HEK293T cells *versus* oocytes (39). Specifically, certain mutations that cause large shifts in EC₅₀ or lead to nonfunctional receptors in HEK293T cells often have little to no influence on function in oocytes. In agreement, we find that mutations in α M4 that have little effect on nAChR function in oocytes, such as the α D407A and α R429A, cause a dramatic reduction in function in HEK293T cells. Similar trends have also been observed with other mutations, such as ε C470A and β D445A, δ D449A and ε D435A, both here and in other studies (29, 43).

The observed difference in the functional effects of M4 mutations in HEK293T cells versus oocytes can be attributed to several factors, including different intracellular chaperones, proximal membrane proteins, or the lipid composition of the surrounding membrane. While speculative, we favor the latter hypothesis given that the mutations we have investigated here are within the lipid-exposed aM4 helix. In addition, previous studies have shown that the biophysical properties of the WT receptor are very similar between the two systems (44). The lipid composition of oocytes appear to be quite similar to that of a neuronal membrane, although the defined lipid profile in both sets of membranes does vary depending on the methods used for quantifying the different lipids (45-48). On the other hand, the lipid composition of cultured HEK293T cells clearly lacks polyunsaturated fatty acids (49). Polyunsaturated fatty acids make up between 40 and 50% of fatty acids in neuronal membranes but less than 20% in cultured HEK293T cells (50, 51). This change in lipid composition is likely to have a dominant effect on both the fluidity of the bilayer and the formation of lipid nanodomains. Given that lipid composition



has a dramatic effect on the coupling of binding and gating in the *Torpedo* muscle–like nAChR function, it may be that the effects of mutations studied here are more dramatic when the nAChR is imbedded in an unfavorable membrane environment.

Experimental procedures

Molecular biology and electrophysiology

Mutants were created from WT human $\alpha 1$, $\beta 1$, δ , and ε nAChR sequences in the pcDNA3 vector using QuikChange Site-Directed Mutagenesis kits (Agilent) and verified by sequencing (35). The resulting vectors were linearized and capped circular RNA (cRNA) produced by *in vitro* transcription using the mMESSAGE mMACHINE T7 kit (Ambion).

Stage V-VI oocytes were injected with 5 ng of mutated α 1 subunit cRNA along with 2.5 ng each of WT β 1, δ , and ε subunit cRNA, and allowed to incubate 1 to 4 days at 16 °C in ND96⁺ buffer (96 mM NaCl, 2 mM KCl, 1 mM MgCl₂, 1 mM CaCl₂ 50 mM Hepes, 2 mM pyruvate, 10 ml/l penicillin/streptomycin, 50 mg/ml kanamycin, pH = 7.5). Whole-cell currents were measured in response to ACh concentration jumps using a TEVC apparatus (OC-725C oocyte clamp) in the presence of 1 μ M atropine to prevent activation of endogenous calcium-activated chloride channels via muscarinic ACh receptors. Whole-cell currents were recorded in Hepes buffer (96 mM NaCl, 2 mM KCl, 1.8 mM BaCl₂, 1 mM MgCl₂, and 10 mM Hepes, pH 7.3), with the transmembrane voltage clamped at voltages between -20 mV and -80 mV, depending on the levels of protein expression. Dose responses for each mutant were acquired from at least two different batches of oocytes. Each individual dose response was fit with a variable slope sigmoidal dose-response curve. Plots were created using GraphPad Prism (GraphPad Software, Inc), and the individual pEC₅₀ (-logEC₅₀) values and Hill coefficients from each experiment averaged to give the presented values ± standard deviation. For the presented dose-response curves, the individual dose responses were normalized, and then each data point averaged. Curve fits of the averaged data are presented, with the error bars representing the standard error. Statistical significance was tested using a one-way ANOVA, followed by Dunnet's post hoc test.

Cell culture

HEK293T cells were maintained in a humidified atmosphere at 37 °C with 5% CO₂, in Dulbecco's modified Eagle's medium supplemented with 5% heat-inactivated fetal bovine serum, 5% bovine calf serum, and 1% antibiotic–antimycotic (Gibco). Cells were plated in either 6-well dishes for the membrane potential assay or 12 cm dishes for the radioligand-binding assay at a density of 1.2 million cells/well. Transient transfection using polyethylenimine proceeded with a 2:1:1:1 ratio of nAChR subunits, α 1: β 1: δ : ϵ , adding up to a total of 2 µg of DNA for the membrane potential assay or 20 µg for the radioligand-binding assay. After 24 h, the cells were washed with 1× PBS at pH 7.4 and detached using 0.05% trypsin–EDTA, before they were resuspended in Dulbecco's modified Eagle's medium containing 1% fetal bovine serum/ bovine calf serum and 1% antibiotic–antimycotic. Cells destined for the membrane potential assay were then seeded in a black-walled, clear-base, poly-D-lysine–coated, 384-well plate at a density of 45,000 cells/well. Cells destined for the radioligand-binding assay were transferred in 15 ml Falcon tubes, centrifuged at 1000 rpm for 2 min, and resuspended in 3.5 ml of phosphate ringer buffer (PRB; 140 mM KCl, 5.4 mM NaCl, 1.8 mM CaCl₂, 1.7 mM MgCl₂, 25 mM Hepes, 30 mg/l bovine serum albumin, pH = 7.4).

Membrane potential assay

Changes in membrane potential in HEK293T cells transfected with WT and mutant nAChRs were measured using the FLIPR Tetra system (Molecular Devices). A voltage-sensitive dye, DiSBAC1(3) (FIVEphoton Biochemicals), was prepared by dissolving the powder in dimethyl sulfoxide. An assay buffer containing 2.5 µM DiSBAC1(3), 200 µM Direct Blue 71 (Sigma-Aldrich), and 1× Hanks' balanced salt solution, 20 mM Hepes, pH 7.4 was freshly prepared as well. Cell medium was removed from the 384-well plate and replaced with 20 µl of the assay buffer. Cells were then incubated with the assay buffer at 37 °C for 30 min before using the FLIPR Tetra system to run the experiment. Prior to any additions, baseline fluorescence levels ($\lambda_{\text{excitation}} = 510-545 \text{ nm}$, $\lambda_{\text{emission}} = 565-625 \text{ nm}$) were measured every 2 s for 20 s. At 20 s, 10 µl of each ACh concentration was added onto each well, and the emitted fluorescence was monitored every 2 s for a total of 1000 s. In each experiment, four wells for each concentration were averaged to yield the presented curves in Fig. S2. The change in fluorescence for each ACh concentration was taken as the difference in fluorescence at 1000 s and the fluorescence prior to ACh addition. The change in fluorescence at each ACh concentration was then normalized to the maximum change in fluorescence and fit with a variable slope sigmoidal doseresponse curve. Plots were created using GraphPad Prism, and the individual pEC₅₀ (-logEC₅₀) values and Hill coefficients from each experiment averaged to give the presented values ± standard deviation.

Radioligand-binding assays

Cell surface in HEK293T cells was determined using the high-affinity radiolabeled toxin, [^{125}I]- α -BTX. About 450 µl of HEK293T cells suspended in PRB were transferred into 2 ml Eppendorf tubes for each replicate of each mutant in the experiment. These cells were then rotated for 1 h at room temperature with a final concentration of 25 µM α -BTX (1:100 ratio of radiolabeled to nonradiolabeled toxin). Following incubation, cells were pelleted and excess α -BTX removed before the cells resuspended in toxin-free PRB. Using a filtration manifold, each sample was filtered through glass GF/C filters (Whatman) for 5 s, followed by 3 × 2 ml washes with PRB. Filters were then allowed to dry under suction for an additional 15 s to remove excess buffer. Bound [^{125}I]- α -BTX

was then quantified by γ counting each filter paper, and nonspecific binding was determined using the same procedure with untransfected cells.

Homology models

Homology models of each human adult muscle nAChR subunit were created based on the 2.7 Å resolution structure of the muscle nAChR from *Torpedo* (Protein Data Bank: 6UWZ) (14) using the Swiss-Model online server (https://swissmodel. expasy.org/).

Data availability

All data described here are available within the article and supporting information.

Supporting information—This article contains supporting information.

Acknowledgments—The authors thank Anais Santos and Shobhitha Balasubramaniam for their technical assistance.

Author contributions—M. J. T., J. A. D., and J. E. B. conceptualization; M. J. T., J. A. D., C. H. E., and A. V. investigation; M. J. T. and J. E. B. writing-reviewing & editing; M. J. T. visualization; P. M. G. and J. E. B. supervision; J. E. B. funding acquisition.

Funding and additional information—This work was supported by a grant from Natural Sciences and Engineering Research Council of Canada (grant no.: 113312) to J. E. B.

Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations—The abbreviations used are: α -BTX, α -bungarotoxin; ACh, acetylcholine; CMS, congenital myasthenic syndrome; cRNA, circular RNA; ECD, extracellular domain; ELIC, *Erwinia* ligand-gated ion channel; GLIC, *Gloebacter* ligand-gated ion channel; HEK293T, human embryonic kidney 293T cell line; nAChR, nicotinic acetylcholine receptor; pLGIC, pentameric ligand-gated ion channel; PRB, phosphate ringer buffer; TEVC, twoelectrode voltage clamp; TMD, transmembrane domain.

References

- Baenziger, J. E., Hénault, C. M., Therien, J. P. D., and Sun, J. (2015) Nicotinic acetylcholine receptor–lipid interactions: mechanistic insight and biological function. *Biochim. Biophys. Acta* 1848, 1806–1817
- Barrantes, F. J. (2015) Phylogenetic conservation of protein–lipid motifs in pentameric ligand-gated ion channels. *Biochim. Biophys. Acta* 1848, 1796–1805
- Thompson, M. J., and Baenziger, J. E. (2020) Structural basis for the modulation of pentameric ligand-gated ion channel function by lipids. *Biochim. Biophys. Acta Biomembr.* 1862, 183304
- daCosta, C. J. B., Medaglia, S. A., Lavigne, N., Wang, S., Carswell, C. L., and Baenziger, J. E. (2009) Anionic lipids allosterically modulate multiple nicotinic acetylcholine receptor conformational equilibria. *J. Biol. Chem.* 284, 33841–33849
- daCosta, C. J. B., and Baenziger, J. E. (2009) A lipid-dependent uncoupled conformation of the acetylcholine receptor. *J. Biol. Chem.* 284, 17819–17825

- daCosta, C. J. B., Dey, L., Therien, J. P. D., and Baenziger, J. E. (2013) A distinct mechanism for activating uncoupled nicotinic acetylcholine receptors. *Nat. Chem. Biol.* 9, 701–707
- 7. Thompson, M. J., and Baenziger, J. E. (2020) Ion channels as lipid sensors: from structures to mechanisms. *Nat. Chem. Biol.* **16**, 1331–1342
- Hénault, C. M., Sun, J., Therien, J. P. D., daCosta, C. J. B., Carswell, C. L., Labriola, J. M., *et al.* (2015) The role of the M4 lipid-sensor in the folding, trafficking, and allosteric modulation of nicotinic acetylcholine receptors. *Neuropharmacology* 96, 157–168
- Lasalde, J. A., Tamamizu, S., Butler, D. H., Vibat, C. R. T., Hung, B., and McNamee, M. G. (1996) Tryptophan substitutions at the lipid-exposed transmembrane segment M4 of Torpedo californica acetylcholine receptor govern channel gating. *Biochemistry* 35, 14139–14148
- Bouzat, C., Roccamo, A. M., Garbus, I., and Barrantes, F. J. (1998) Mutations at lipid-expossed residues of the acetylcholine receptor affect its gating kinetics. *Mol. Pharmacol.* 54, 146–153
- Bouzat, C., Barrantes, F. J., and Sine, S. M. (2000) Nicotinic receptor fourth transmembrane domain: hydrogen bonding by conserved threonine contributes to channel gating kinetics. *J. Gen. Physiol.* 115, 663–671
- Bouzat, C., Gumilar, F., del Carmen Esandi, M., and Sine, S. M. (2002) Subunit-selective contribution to channel gating of the M4 domain of the nicotinic receptor. *Biophys. J.* 82, 1920–1929
- Shen, X.-M., Deymeer, F., Sine, S. M., and Engel, A. G. (2006) Slowchannel mutation in acetylcholine receptor αM4 domain and its efficient knockdown. *Ann. Neurol.* 60, 128–136
- Rahman, M., Teng, J., Worrell, B. T., Karlin, A., Stowell, M. H. B., Hibbs, R. E., *et al.* (2020) Structure of the native muscle-type nicotinic receptor and inhibition by snake venom toxins article structure of the native muscle-type nicotinic receptor and inhibition by snake venom toxins. *Neuron* 106, 1–11
- Unwin, N. (2020) Protein-lipid architecture of a cholinergic postsynaptic membrane. *IUCrJ* 7, 1–8
- Zarkadas, E., Pebay-Peyroula, E., Thompson, M. J., Schoehn, G., Uchański, T., Steyaert, J., *et al.* (2022) Conformational transitions and ligand-binding to a muscle-type acetylcholine receptor. *Neuron* 110, 1358–1370
- Rahman, M., Basta, T., Teng, J., Lee, M., Worrell, B. T., Stowell, M. H. B., et al. (2022) Structural mechanism of muscle nicotinic receptor desensitization and block by curare. Nat. Struct. Mol. Biol. 29, 386–394
- Hénault, C. M., Govaerts, C., Spurny, R., Brams, M., Estrada-Mondragon, A., Lynch, J. W., *et al.* (2019) A lipid site shapes the agonist response of a pentameric ligand-gated ion channel. *Nat. Chem. Biol.* 15, 1156–1164
- Butler, A. S., Lindesay, S. A., Dover, T. J., Kennedy, M. D., Patchell, V. B., Levine, B. A., *et al.* (2009) Importance of the C-terminus of the human 5-HT3A receptor subunit. *Neuropharmacology* 56, 292–302
- Haeger, S., Kuzmin, D., Detro-Dassen, S., Lang, N., Kilb, M., Tsetlin, V., et al. (2010) An intramembrane aromatic network determines pentameric assembly of Cys-loop receptors. *Nat. Struct. Mol. Biol.* 17, 90–98
- Carswell, C. L., Hénault, C. M., Murlidaran, S., Therien, J. P. D., Juranka, P. F., Surujballi, J. A., *et al.* (2015) Role of the fourth transmembrane α helix in the allosteric modulation of pentameric ligand-gated ion channels. *Structure* 23, 1655–1664
- 22. Alcaino, C., Musgaard, M., Minguez, T., Mazzaferro, S., Faundez, M., Iturriaga-Vasquez, P., *et al.* (2017) Role of the cys loop and transmembrane domain in the allosteric modulation of $\alpha 4\beta 2$ nicotinic acetylcholine receptors. *J. Biol. Chem.* **292**, 551–562
- Cory-Wright, J., Alqazzaz, M. A., Wroe, F., Jeffreys, J., Zhou, L., and Lummis, S. C. R. (2018) Aromatic residues in the fourth transmembranespanning helix M4 are important for GABAρ receptor function. ACS Chem. Neurosci. 9, 284–290
- Noviello, C. M., Gharpure, A., Mukhtasimova, N., Borek, D., Sine, S. M., Hibbs, R. E., *et al.* (2021) Structure and gating mechanism of the a7 nicotinic acetylcholine receptor. *Cell* 184, 2121–2134
- **25.** Hénault, C. M., Juranka, P. F., and Baenziger, J. E. (2015) The M4 transmembrane α-helix contributes differently to both the maturation and function of two prokaryotic pentameric ligand-gated ion channels. *J. Biol. Chem.* **290**, 25118–25128



- 26. Thompson, M. J., Domville, J. A., and Baenziger, J. E. (2020) The functional role of the α M4 transmembrane helix in the muscle nicotinic acetylcholine receptor probed through mutagenesis and co-evolutionary analyses. *J. Biol. Chem.* **295**, 11056–11067
- Mitra, A., Bailey, T. D., and Auerbach, A. (2004) Structural dynamics of the M4 transmembrane segment during acetylcholine receptor gating. *Structure* 12, 1909–1918
- Rudell, J. C., Borges, L. S., Yarov-Yarovoy, V., and Ferns, M. (2020) The MX-helix of muscle nAChR subunits regulates receptor assembly and surface trafficking. *Front. Mol. Neurosci.* 13, 48
- 29. Ealing, J., Webster, R., Brownlow, S., Abdelgany, A., Oosterhuis, H., Muntoni, F., *et al.* (2002) Mutations in congenital myasthenic syndromes reveal an ε subunit C-terminal cysteine, C470, crucial for maturation and surface expression of adult AChR. *Hum. Mol. Genet.* **11**, 3087–3096
- **30.** Tang, B., and Lummis, S. C. R. (2018) The roles of aromatic residues in the glycine receptor transmembrane domain. *BMC Neurosci.* **19**, 53
- Therien, J. P. D., and Baenziger, J. E. (2017) Pentameric ligand-gated ion channels exhibit distinct transmembrane domain archetypes for folding/ expression and function. *Sci. Rep.* 7, 450
- 32. Mesoy, S. M., Jeffreys, J., and Lummis, S. C. R. (2019) Characterization of residues in the 5-HT3 receptor M4 region that contribute to function. ACS Chem. Neurosci. 10, 3167–3172
- 33. da Costa Couto, A. R. G. M., Price, K. L., Mesoy, S., Capes, E., and Lummis, S. C. R. (2020) The M4 helix is involved in α7 nACh receptor function. ACS Chem. Neurosci. 11, 1406–1412
- Carswell, C. L., Sun, J., and Baenziger, J. E. (2015) Intramembrane aromatic interactions influence the lipid sensitivities of pentameric ligandgated ion channels. *J. Biol. Chem.* 290, 2496–2507
- 35. Domville, J. A., and Baenziger, J. E. (2018) An allosteric link connecting the lipid-protein interface to the gating of the nicotinic acetylcholine receptor. *Sci. Rep.* 8, 3898
- 36. Ortiz-Acevedo, A., Melendez, M., Asseo, A. M., Biaggi, N., Rojas, L. V., and Lasalde-Dominicci, J. A. (2004) Tryptophan scanning mutagenesis of the γM4 transmembrane domain of the acetylcholine receptor from Torpedo californica. J. Biol. Chem. 279, 42250–42257
- 37. Lee, Y. H., Li, L., Lasalde-Dominicci, J. A., Rojas, L. V., McNamee, M. G., Ortiz-Miranda, S. I., *et al.* (1994) Mutations in the M4 domain of Torpedo californica acetylcholine receptor dramatically alter ion channel function. *Biophys. J.* 66, 646–653
- 38. Caballero-Rivera, D., Cruz-Nieves, O. A., Oyola-Cintrón, J., Torres-Núñez, D. A., Otero-Cruz, J. D., and Lasalde-Dominicci, J. A. (2012) Tryptophan scanning mutagenesis reveals distortions in the helical structure of the δM4 transmembrane domain of the Torpedo californica nicotinic acetylcholine receptor. *Channels* 6, 111–123

- 39. Crnjar, A., Mesoy, S. M., Lummis, S. C. R., and Molteni, C. (2021) A single mutation in the outer lipid-facing helix of a pentameric ligandgated ion channel affects channel function through a radially-propagating mechanism. *Front. Mol. Biosci.* 8, 644720
- 40. Mesoy, S. M., and Lummis, S. C. R. (2021) M4, the outermost helix, is extensively involved in opening of the $\alpha4\beta2$ nACh receptor. *ACS Chem. Neurosci.* 12, 133–139
- **41.** Gharpure, A., Teng, J., Zhuang, Y., Noviello, C. M., Walsh, R. M., Cabuco, R., *et al.* (2019) Agonist selectivity and ion permeation in the $\alpha 3\beta 4$ ganglionic nicotinic receptor. *Neuron* **104**, 501–511
- 42. Walsh, R. M., Roh, S.-H., Gharpure, A., Morales-Perez, C. L., Teng, J., and Hibbs, R. E. (2018) Structural principles of distinct assemblies of the human α4β2 nicotinic receptor. *Nature* 557, 261–265
- Strikwerda, J. R., and Sine, S. M. (2021) Unmasking coupling between channel gating and ion permeation in the muscle nicotinic receptor. *Elife* 10, e66225
- 44. Zhang, Y., Chen, J., and Auerbach, A. (1995) Activation of recombinant mouse acetylcholine receptors by acetylcholine, carbamylcholine and tetramethylammonium. *J. Physiol.* 486, 189–206
- 45. Hill, W. G., Southern, N. M., MacIver, B., Potter, E., Apodaca, G., Smith, C. P., *et al.* (2005) Isolation and characterization of the Xenopus oocyte plasma membrane: a new method for studying activity of water and solute transporters. *Am. J. Physiol. Renal Physiol.* 289, 217–224
- Opekarová, M., and Tanner, W. (2003) Specific lipid requirements of membrane proteins - a putative bottleneck in heterologous expression. *Biochim. Biophys. Acta Biomembr.* 1610, 11–22
- **47.** Santiago, J., Guzmán, G. R., Rojas, L. V., Marti, R., Asmar-Rovira, G. A., Santana, L. F., *et al.* (2001) Probing the effects of membrane cholesterol in the Torpedo californica acetylcholine receptor and the novel lipidexposed mutation αC418W in Xenopus oocytes. *J. Biol. Chem.* **276**, 46523–46532
- 48. Stith, B. J., Hall, J., Ayres, P., Waggoner, L., Moore, J. D., and Shaw, W. A. (2000) Quantification of major classes of Xenopus phospholipids by high performance liquid chromatography with evaporative light scattering detection. *J. Lipid Res.* 41, 1448–1454
- Else, P. L. (2020) The highly unnatural fatty acid profile of cells in culture. Prog. Lipid Res. 77, 101017
- 50. Symons, J. L., Cho, K. J., Chang, J. T., Du, G., Waxham, M. N., Hancock, J. F., *et al.* (2021) Lipidomic atlas of mammalian cell membranes reveals hierarchical variation induced by culture conditions, subcellular membranes, and cell lineages. *Soft Matter* 17, 288–297
- Ingólfsson, H. I., Carpenter, T. S., Bhatia, H., Bremer, P. T., Marrink, S. J., and Lightstone, F. C. (2017) Computational lipidomics of the neuronal plasma membrane. *Biophys. J.* 113, 2271–2280